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ABSTRACT 
 Follicular lymphoma (FL) is one of the commonest entities of non-Hodgkin´s 
lymphoma (NHL) worldwide. Many patients with advanced stages of FL achieve a very 
good partial remission, but few, if any, can be cured. Thus, more effective treatment 
regimens are indispensable. As evading cell death is paramount to tumour progression, the 
aim of the present investigation was to characterize novel inducers of apoptosis in FL cell 
lines. 
 Initially, we examined the action of a novel small molecule inhibitor of Bcl-2 
oncoprotein, HA14-1, demonstrating that FL cell lines are sensitive to its single-agent pro-
apoptotic action, and analysing: i) the temporal and quantitative relationship between two 
apoptotic events pivotal in HA14-1-evoked apoptosis (mitochondrial breach and caspase 
activation); ii) cell cycle-specificity of HA14-1-triggered apoptosis.  
 FL is mostly an indolent disease, with multiple courses of chemotherapy severely 
impairing the quality of patients´ life. Thus, we went on to study the effects of a natural 
polyphenol curcumin, known to exert anti-proliferative and/or pro-apoptotic effects in 
several tumour cell lines. The compound has superior safety records from clinical trials, and 
has shown promising chemopreventive and/or anticancer properties in animal models, and 
in humans. FL cells were sensitive to the action of curcumin, with significant cessation of 
cell growth observed at reportedly attainable in vivo concentration. Employing flow 
cytometry and biochemical approaches, we demonstrated that curcumin-induced apoptosis 
is caspase-dependent, associated with ROS generation and lysosomal rupture, and can be 
significantly enhanced by ascorbic acid. We also investigated gene expression changes 
during curcumin-triggered apoptosis in FL cell line HF4.9, applying a new technology of 
bead chip microarrays. Complex reprogramming was associated with induction of apoptosis 
in curcumin-treated HF4.9 cells, including genes encoding tumour and metastasis 
suppressors, proteins involved in the regulation of cell adhesion and migration, or 
transcription/splicing factors. Importantly, CXCR4, a chemokine receptor in control of cell 
migration that reportedly contributes to local and distant tumour dissemination, was down-
regulated in all FL cell lines tested. Finally, specificity of CXCR4 down-regulation in 
different cell death contexts was investigated. 
 Overall, the thesis advances the current knowledge on stimuli to engage apoptotic 
response in FL cells, indicating that both Bcl-2 inhibitors and natural compounds such as 
curcumin may prove beneficial for the management of FL, and warranting their further 
investigation in vivo. 
 
National Library of Medicine Classification: QU 350, QU 375, QZ 350, WH 525 
Medical Subject Headings: Apoptosis; Apoptosis Regulatory Proteins; Cell Death; 
Curcumin; Lymphoma, Follicular; Mitochondria; Microarray Analysis 

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"Life has two rules: Number One, never quit; 
Number Two, always remember rule number one" 
Duke Ellington 
 

 ACKNOWLEDGEMENTS 
 
 
This study was carried out in the Department of Clinical Microbiology, University 
of Kuopio, during 2005-2006.  
 
I am grateful to my principal supervisor, Professor Jukka Pelkonen, for providing 
working space, and making constant attempts to reveal the beauty of severe Finnish 
winter and virtues of cross-country skiing. 
 
I owe my sincere thanks for the excellent technical assistance and friendship from 
Eila Pelkonen. Many thanks also for all the self-picked forest fruits, and a taste of 
wonderful Chinese cuisine! 
 
I would like to thank Juhani Soini and Päivi Junni from the Microarray Centre at 
Turku Centre for Biotechnology for all the help and advice on design and analysis of 
microarray experiments, and Professor Andrzej Deptala, Department of 
Hematology, Oncology and Internal Medicine, CSKMSWiA Hospital, Warsaw, for 
friendship, support, fruitful collaboration and discussions. 
 
Professors Zbigniew Darzynkiewicz (New York Medical College, Valhalla, New 
York, USA) and Professor Faustino Mollinedo (Universidad de Salamanca, 
Salamanca, Spain), the official reviewers of this thesis, are greatly acknowledged for 
their feedback and support. I am deeply grateful for all valuable comments and 
corrections provided. 
 
I dedicate my warm thanks to Donald for the fruitful collaboration, everlasting 
encouragement and patience, and sharing ups and downs. I would not manage to 
proceed with my work without your support. I did my best to do the best I could, but 
all in all you are the one who got me through. 
 
I would like to express a sincere gratitude to my closest family, especially my 
parents Grazyna and Janusz, and sister Natalia, and also Ewa and Pawel, uncle 
Zdzislaw, and aunt and uncle Roza and Zdzislaw for continuous support from the 
distance. To all my friends spread all over the world - for encouragement and 
wonderful time we spent together - thank you! Magda and Krzys – our time together 
in Kuopio, and later on in Turku, rocked!! I hope future holds more such evenings 
and nights together!  
 
Finally, I am tremendously grateful for all the encouragement given to me by 
follicular lymphoma patients, their friends and families interested in my research 
work into curcumin action. With all my heart I wish you nothing but successes in the 
fight against the malignancy! 
 This work was financed from the Kuopio University Hospital grant. I was also 
supported by the Centre for International Mobility (CIMO) scholarship. Moreover, 
the generous support from L´Oréal –Poland (scholarship for Women in Science 
2006/2007) is gratefully acknowledged. 
 
Kuopio,  
 
Joanna Skommer
 ABBREVIATIONS 
 
AIF apoptosis inducing factor 
ANT adenine nucleotide transporter 
AO acridine orange 
AP-1 activating protein-1 
Bax Bcl-2 associated X protein 
Bcl-2 B-cell lymphoma 2 protein 
Bcl-6 B-cell lymphoma 6 protein 
Bcl-XL Bcl-2-related gene (large variant) 
b-FGF basic fibroblast growth factor 
BH Bcl-2 homology 
CARD caspase-activation recruitment domain 
COX2 cyclooxygenase-2 
CsA cyclosporine A 
CXCR4 CXC chemokine receptor 4 
CypD cyclophilin D 
Da Dalton 
DISC death-inducing signaling complex 
DR death receptor 
Drp1 dynamin-related protein 1 
Endo G endonuclease G 
ER endoplasmic reticulum 
FADD Fas Associated Death Domain 
FL follicular lymphoma 
FLICA fluorochrome-labeled inhibitor of caspases 
fmk fluoromethylketone 
Gas2 growth-arrest specific 2 protein 
GC germinal center 
HA14-1 ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-
 chromene-3-carboxylate 
HIF-1 hypoxia-inducible factor-1 
HtrA2/Omi high-temperature requirement protein A2 
IAP inhibitor of apoptosis protein 
ICAD inhibitor of caspase-activated deoxyribonuclease 
IM inner membrane 
mAb monoclonal antibody 
MAC mitochondrial apoptosis-induced channel 
MMP matrix metalloproteinase 
MOMP mitochondrial outer membrane permeabilization 
NAC N-acetylcysteine 
NAO nonyl-acridine orange 
 OM outer membrane 
Opa1 optic atrophia 1 
PARP poly (ADP-ribose) polymerase 
PKC protein kinase C 
PTP permeability transition pore 
RIP receptor-interacting protein 
ROS reactive oxygen species 
SDF-1 stromal cell-derived factor-1  
Smac/DIABLO second mitochondria-derived activator of caspase/direct IAP-
 binding protein with low PI 
VDAC voltage-dependent anion channel 
VEGF vascular endothelial growth factor 
tBid truncated Bid 
TIMP-1 tissue inhibitor of metalloproteinase 
zVAD benzyloxycarbonyl-Val-Ala-Asp 
  
 
 LIST OF ORIGINAL PUBLICATIONS 
 
 
The thesis is based on the following original publications, which are referred to in 
the text by the Roman numerals: 
 
I Wlodkowic D, Skommer J, Pelkonen J (2006) Multiparametric analysis of 
HA14-1-triggered apoptosis in follicular lymphoma cells. Leukemia Res 
30(9):1187-1192 
 
II Skommer J, Wlodkowic D, Pelkonen J (2006) Cellular Foundation of 
Curcumin-induced Apoptosis in Follicular Lymphoma Cell Lines. Exp Hematol 
34(4):463-74. 
 
III Skommer J, Wlodkowic D, Pelkonen J (2007) Gene expression profiling during 
curcumin-induced apoptosis reveals down-regulation of CXCR4. Exp Hematol 
35(1):84-95 
 
IV Skommer J, Wlodkowic D, Pelkonen J (2007) CXCR4 expression during 
tumour cell death. Leukemia Res Oct 23; [Epub ahead of print] 
 
 
 
The original articles have been reproduced with permission of the copyright holders. 
The thesis includes also previously unpublished data. 

 CONTENTS 
1. INTRODUCTION .........................................................................................................................12 
2. REVIEW OF THE LITERATURE .............................................................................................14 
2.1. FOLICULLAR LYMPHOMA.................................................................................................14 
2.2. APOPTOSIS ............................................................................................................................16 
2.2.1. Apoptosis, necrosis, and others........................................................................................16 
2.2.2. Caspase-controlled hydrolytic eruption in cell death: "the kiss of death" .......................19 
2.2.3. Mitochondrion in cell death – the ultimate valve .............................................................22 
2.3. THE BCL-2 RIDDLE...............................................................................................................30 
2.3.1. Bcl-2 family members.......................................................................................................30 
2.3.4. Outline of current approaches to inhibit Bcl-2 ................................................................33 
2.4. CURCUMIN ............................................................................................................................35 
2.4.1. Targeting of apoptotic pathways by curcumin .................................................................36 
2.4.2. Successes and failures of curcumin in clinical trials........................................................40 
3 AIMS OF THE STUDY .................................................................................................................42 
4 MATERIALS AND METHODS ...................................................................................................43 
4.1. CELL LINES AND CULTURING (I-IV) ..........................................................................................43 
4.2. CELL TREATMENT EXPERIMENTS ..............................................................................................43 
4.3. CELL PROLIFERATION AND VIABILITY ASSAYS..........................................................................44 
4.3.1. [3H]-Thymidine incorporation assay (II) .........................................................................44 
4.3.2. Trypan blue staining (II) ..................................................................................................45 
4.4. APOPTOSIS DETECTION .............................................................................................................45 
4.5.1. Morphological assessment (II) .........................................................................................45 
4.5.2. Quantification of fractional DNA content (II)..................................................................45 
4.5.3. Conformational DNA/RNA changes (II, III, IV)...............................................................45 
4.5.4. Cell membrane permeabilization (II) ...............................................................................46 
4.5.5. Mitochondrial membrane potential depolarisation (I, II) ................................................46 
4.5.6. Cytochrome c release (II).................................................................................................47 
4.5.7. Caspase activation (I, II, IV) ............................................................................................47 
4.5.8. Multiparametric flow cytometry assays (I).......................................................................47 
4.6. CELL CYCLE ANALYSIS .............................................................................................................48 
4.7. LYSOSOMAL MEMBRANE PERMEABILIZATION (II).....................................................................48 
4.8. DETECTION OF REACTIVE OXYGEN SPECIES (ROS) (II) .............................................................49 
4.9. CELL SURFACE STAINING (III)...................................................................................................49 
4.10. IMMUNOBLOTTING (II, III, IV) ................................................................................................49 
4.10. RNA ISOLATION (III) ..............................................................................................................50 
4.11. LARGE-SCALE GENE EXPRESSION PROFILING (III) ...................................................................50 
4.11.1. Probe preparation ..........................................................................................................50 
4.11.2. Bead chip microarrays ...................................................................................................51 
4.11.3. qRT- PCR .......................................................................................................................53 
4.12. DATA ANALYSIS......................................................................................................................53 
4.12.1. Microarray data analysis (III) .......................................................................................53 
5. RESULTS AND DISCUSSION ....................................................................................................55 
 5.1. HA14-1 AS AN EFFECTIVE INDUCER OF APOPTOSIS (PUBLICATION I) ........................................55 
5.2. CHARACTERIZATION OF CURCUMIN-INDUCED APOPTOSIS (PUBLICATION II) ............................57 
5.3. GLOBAL GENE EXPRESSION REPROGRAMMING INDUCED BY CURCUMIN (PUBLICATION III)......59 
5.3.1. CXCR4..............................................................................................................................60 
5.3.2. CD20 ................................................................................................................................63 
5.4. CXCR4 DOWN-REGULATION IS NOT A COMMON APOPTOSIS-ASSOCIATED EVENT (PUBLICATION 
IV)...................................................................................................................................................65 
6. CONCLUSIONS, CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS ..................67 
 
 
 
 
APPENDIX: ORIGINAL PUBLICATIONS I-IV 
 
 12
1. INTRODUCTION 
All long-living organisms face a formidable challenge dealing with the accumulation 
of genetic lesions over time, which, if amass, manifest themselves as life-threatening 
conditions. One of those is cancer, described as a disease that involves excessive 
proliferation of cells and abandonment of their ability to die. Normally, cells can kill 
themselves in a highly balanced process known as apoptosis, and incapacitated 
execution or regulation of thereof has calamitous consequences, leading to a variety 
of cancers, including B cell follicular lymphoma. Intrinsically, cancer cells are 
primed for death during malignant transformation, and can evade destruction and go 
on to form tumours only upon development of additional protective mechanisms. 
Thus, it is intellectually appealing that a restoration of derailed cell death pathways 
should preferentially kill cancer cells over their non-malignant counterparts. 
Additionally, the anti-tumour efficacy of anticancer drugs is mostly ascribed to their 
ability to induce apoptosis, and other forms of cell death, such as autophagic cell 
death, caspase-independent apoptosis-like cell death, mitotic catastrophe or necrosis. 
Hence, studies aimed to delineate exact mechanisms behind cell demise as well as 
efforts to find novel potent apoptotic inducers are of considerable clinical 
importance and may suggest credible targets for cancer therapy. 
 
A plethora of new apoptosis-based therapies emerges from the understanding of 
mechanisms underlying apoptosis and knowledge on its core components. Both 
drugs directed to inhibit apoptosis-blocking proteins and agents that stimulate or 
restore pro-apoptotic pathways are being extensively studied in vitro and in vivo, 
with emerging efforts towards their translation to the clinics. 
Side effects of conventional chemotherapy represent one of the major obstacles to 
the successful treatment of malignant disorders. In the case of follicular lymphoma, 
the cyclical pattern of relapses necessitates repeated administration of cytotoxic 
drugs, severely decreasing the quality of patients´ life. As the initial therapy of 
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advanced stage FL commonly comprises of a watch and wait strategy until the 
disease becomes symptomatic, the natural compounds with chemopreventive and/or 
anticancer properties and minimal side effects may represent an alternative strategy 
to safely defeat this malignancy.  
 
The present study was primarily focused on the investigation of the pro-apoptotic 
properties of a novel small molecule Bcl-2 inhibitor, HA14-1, and a natural 
compound isolated from the Asian tropical plant Curcuma longa, curcumin, in 
follicular lymphoma cell lines. 
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2. REVIEW OF THE LITERATURE 
2.1. FOLICULLAR LYMPHOMA 
Follicular lymphoma (FL) is one of the commonest subtypes of non-Hodgkin´s 
lymphoma (NHL) worldwide and its incidence is rapidly increasing in western 
countries [de Jong, 2005]. Although mostly a disease of adulthood, FL has also been 
reported in children, in whom it displays localized presentation and more favourable 
prognosis. Typically, the disease exhibits a relatively indolent clinical course. 
However, majority of patients present with disseminated disease already at 
diagnosis, with lymph nodes, spleen, bone marrow, and peripheral blood being the 
sites most frequently involved in FL presentation. Moreover, cyclical pattern of 
induced remissions and relapses, with 25-60% of cases where transformation to a 
more aggressive histology occurs, is common [Horning and Rosenberg, 1994]. The 
median survival ranges from 8 to 12 years, yet after the initial relapse both response 
rate and relapse-free survival time tend to decrease, resulting in a median survival of 
only 4-5 years [Johnson et al., 1995]. The management options in the treatment of 
follicular lymphoma include watchful observation [Advani et al., 2004], alkylating 
agents, anthracyclines, purine nucleoside analogs, radiation therapy, combination 
chemotherapy, interferon, radiolabeled and unlabeled monoclonal antibodies (with 
revolutionizing chimeric anti-CD20 mAb rituximab), and autologous bone marrow 
transplantation (BMT) or peripheral blood stem-cell transplantation (PBSCT) 
[Gandhi and Marcus, 2005; Fisher et al., 2005; Coiffier 2005; Hiddemann et al., 
2005]. Although the overwhelming majority of patients with advanced stages of FL 
achieve a very good partial remission, few achieve complete remission, and even 
fewer, if any, can be cured. Dose intensification has the potential to eradicate disease 
completely, but is limited by its treatment-related short-term and long-term toxicity. 
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Follicular lymphoma is a tumour of peripheral B lymphocytes representing 
malignant counterparts of normal germinal centre B cells, and histologically it 
recapitulates the architecture and cytologic features of the normal secondary 
lymphoid follicle. Follicular center lymphoma B cells express surface 
immunoglobulin (sIg) and are CD19+, CD20+, CD10+/-, and CD5-. FL has been 
classically associated with the translocation t(14;18)(q32;q21) leading to the 
rearrangement of the BCL-2 gene in 70 to 95% of reported tumours and 
accumulation of follicle center cells with prolonged survival. The uniform 
expression of Bcl-2 by FL cells contrasts with their exquisite sensitivity to treatment 
in vivo and explicit propensity to undergo spontaneous apoptosis in vitro. 
Additionally, of FL cases, 10-20% lack Bcl-2 over-expression and yet still exhibit 
inhibition of apoptosis. It has been thus concluded that Bcl-2 over-expression per se 
cannot explain the pathogenesis and/or clinical behaviour of this malignancy. 
Indeed, FL cells display a unique pattern of antiapoptotic protein expression 
compared with the balance of anti- and pro-apoptotic proteins observed in normal 
germinal center (GC) B cells [Gulmann et al., 2005; de Jong, 2005; Ghia et al., 
1998]. Activation of the PI3K/AKT pathway, over-expression of MCL-1 and 
survivin, have all been proposed as contributing mechanisms. Furthermore, Bcl-XL 
has been suggested to play a pivotal role in the control of survival of FL cells in 
vitro, and its over-expression has been associated with adverse prognosis in FL 
subjects [Zhao et al., 2004; Ghia et al., 1998]. Moreover, tumour microenvironment 
signals, such as CD40 receptor ligation, interleukin-4 (IL-4) receptor stimulation, or 
the interaction of the integrin ligand VCAM-1 with its receptor, appear to contribute 
to FL cell survival in vivo through the up-regulation of death-inhibiting proteins 
[Ghia et al., 1998; Taylor et al. 1999]. Importantly, the transformed lymphomas 
retain the t(14;18) translocation and usually acquire multiple, complex new 
chromosomal abnormalities (at least one karyotypic abnormality in addition to 
t(14;18), with an average of six alterations) [Horsman et al., 2001]. For instance, in 6 
to 14% of FLs, predominantly FLs grade 3B harbouring a diffuse large B-cell 
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lymphoma (DLBL) component, the rearrangements involving the BCL6 proto-
oncogene locus (3q27) have been encountered. Genome-wide analysis of the DNA 
copy-number changes in FL and transformed/relapsed biopsies revealed multiple 
genomic aberrations acquired upon transformation. Some of the genes within 
regions of gain/amplification or loss were differentially expressed, including CUTL1 
which regulates normal B lymphopoiesis and has been correlated with lymphoid 
abnormalities in mice [Martinez-Climent et al., 2003; Sinclair et al., 2001]. Finally, 
based on distinct transformation-associated gene expression profiles, 2 groups of FL 
patients, with an increase or decrease in the expression of MYC and its target genes, 
can be discriminated [Lossos et al. 2002]. 
  
2.2. APOPTOSIS 
 
"Life is pleasant. Death is peaceful. It's the transition that's troublesome"  
Isaac Asimov 
2.2.1. Apoptosis, necrosis, and others 
Apoptosis (also referred to as type 1 programmed cell death) is a genetically 
controlled event central to the development, homeostasis and disease, with 
compelling evidence that shows its evolutionarily conserved mechanism. For cell 
death to be classified as apoptotic, a pattern of molecular events and morphological 
changes, including prominent condensation of cytoplasm, rounding up, chromatin 
condensation to compact and simple geometric figures, loss of mitochondrial 
membrane potential, karyorhexis, blebbing with maintenance of membrane integrity 
(zeiosis) and plasma-membrane asymmetry coupled to the display of phagocytosis 
markers on the cell surface [Leist and Jaattela, 2001; Edinger and Thompson, 2004] 
must be observed. Caspase activation is traditionally considered a hallmark of 
apoptosis, as is the absence of autophagocytosis.  
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Several models defining the processes of caspase-independent cell death have been 
recently described, and include mitotic catastrophe (a default pathway after mitotic 
failure and development of aneuploid cells), autophagic cell death or necrosis.  
In numerous biological systems the cell´s suicide programme involves the 
autophagic/lysosomal compartment. Accordingly, the autophagic cell death (type 2 
programmed cell death) describes cell demise morphologically distinct from 
apoptosis, with early degradation of organelles but preservation of cytoskeletal 
elements until late stages, and late (if any) caspase activation and DNA 
fragmentation. It results from excessive levels of cellular macroautophagy, a 
degradative strategy conserved across taxa that provides a mechanism for the 
turnover of damaged and/or excessive organelles and long-lived proteins [Levine 
and Yuan, 2005]. Necrosis, on the contrary, is considered as a passive form of cell 
death in which cell dies as a result of bioenergetic catastrophe inflicted by external 
conditions. This is characterized by swelling of organelles (odema), energy 
breakdown, random DNA degradation, relative early breakdown of plasma 
membrane and eventually total cell disintegration that leads to inflammation around 
the dead cells, attributable to the release of the cellular contents and 
proinflammatory molecules [Leist and Jaattela, 2001; Edinger and Thompson, 
2004]. Still, recent discoveries suggest that certain necrotic programmes are driven 
by energy-dependent mechanisms leading to what appears to be a self-determined 
cell fate, shedding doubts on the long-standing tenet that necrosis is merely a passive 
and unregulated cellular collapse [Chiarugi, 2005; Zong et al. 2004].  
Recently, the idea that different cell death modes represent a continuum has been 
gaining momentum. For many years viewed as an exact opposite to necrotic cell 
death, apoptosis can be converted to necrotic phenotype, and stimuli typically 
associated with apoptosis can induce necrosis (and vice versa) [Kalai et al., 2002], 
arguing against the formal, clear-cut distinction. Thus, Majno and Joris denoted 
early stage of primary necrosis during which cell swell as oncosis, sparing the term 
necrosis for changes that occur after cell membrane disruption, which could be 
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applied to cells dying via oncosis or apoptosis [Majno and Joris, 1999]. Similarly, 
there is no clear discrepancy between apoptosis and autophagy, as complex forms of 
cell death with hallmarks of both apoptosis and autophagy have been observed, 
apoptotic process may end with autophagy, and conversely autophagy may provide 
cellular volume reduction prior to apoptosis [Gonzales-Polo et al., 2005; Martinet et 
al., 2005]. Indeed, a lethal process marked by an initial autophagosome 
accumulation, a hallmark of type 2 cell death, can shift to mitochondrion-dependent 
caspase activation, a hallmark of type 1 cell death [Gonzales-Polo et al., 2005]. 
Finally, autophagy can be seen as an option for cells with dysfunctional apoptotic 
machinery that allows avoiding necrosis. Depending on cellular context, autophagy 
may have pro-apoptotic or anti-apoptotic functions, and the molecular mechanism 
determining the switch between these two responses still remains to be elucidated. 
Nevertheless, with emerging evidence for the existence of intermediate cell death 
forms in addition to "classical" apoptosis and necrosis [reviewed by Leist and 
Jäättelä, 2001], the recent proposal on how to define "apoptosis" is "a caspase-
mediated cell death with associated apoptotic morphology", with other forms 
referred as "cell death" until underlying mechanisms are readily distinguished 
[Zhivotovsky, 2004]. Importantly, in many cases features of different forms of cell 
death are observed in the same cell [Levine and Yuan, 2005]. 
 
An estimated 1010 cells die every day in each of us. The killing of an errant cell 
represents, however, only half of the story, and the other half is to securely get rid of 
dying cells. The purpose of classical apoptosis is the efficient display of 
phagocytosis markers on the cell surface well before spillage of cellular constituents, 
allowing for rapid removal of corpses (engulfment) to prevent harmful events 
associated with impaired clearance of dead cells, such as autoimmune disease, tissue 
damage and/or inflammation. Nevertheless, the major "eat-me" signal in mammalian 
cells - translocation of phosphatidylserine (PS) to the outer leaflet of the plasma 
membrane where it becomes accessible to bridging proteins - is independent on 
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caspase activation and can occur during caspase-independent death pathways, and, 
at least in some cell models, during oncosis [Krysko et al., 2004; Lecoeur et al., 
2001]. Therefore, non-apoptotically-dying eukaryotic cells can also be efficiently 
phagocytosed.  
 
2.2.2. Caspase-controlled hydrolytic eruption in cell death: "the kiss of death" 
As mentioned above, apoptosis is traditionally recognized as a death accompanied 
by hydrolysis-driven disintegration mediated by C(ysteine dependent) ASP(artate 
cleaving prote)ASES - caspases. The apoptotic caspases are classified as the initiator 
(or apical) caspases (caspase -2,-8,-9,-10) and the executioner caspases (caspase -3,-
6,-7), depending on their position along the apoptotic cascade [Thornberry and 
Lazebnik, 1998]. To preclude unscheduled cell dismantling, each caspase is 
synthesized as a latent precursor - zymogen that requires an activation event 
[Boatright and Salvesen, 2003; Shi, 2002]. Initiator caspases, such as caspase 8, 9 
and 10, require active dimerization by an adaptor molecule independent of cleavage 
[Boatright et al., 2003; Green, 2005], whereas executioner caspases are activated by 
proteolysis within their interdomain linker [Boatright and Salvesen, 2003].  
 
In general, apoptotic stimuli engage initiator caspases either through death receptors 
stimulation (extrinsic pathway) or through mitochondrial outer membrane 
permeabilization (intrinsic pathway) (Fig. 1), although emerging evidence shows 
that other intracellular compartments and/or organelles (nucleus, endoplasmatic 
reticulum, Golgi, lysosomes) participate in this process [reviewed by Guicciardi et 
al., 2004; Norbury and Zhivotovsky, 2004; Garrido and Kroemer, 2004; and 
Viktorsson et al., 2005]. The receptor mediated pathway is initiated by binding of 
ligands to the tumour necrosis factor (TNF) family of plasma membrane death 
receptors, such as Fas, TNFR1, and the TRAIL receptors DR4 and DR5. Upon 
binding of their cognate ligands, the receptors form trimeric complexes that 
subsequently interact with an adaptor protein FADD, which in turn binds pro-
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caspase-8, resulting in formation of the Death Inducing Signaling Complex (DISC) 
and subsequent activation of caspase 8. Depending on cell type, an initiator caspase-
8 cleaves and activates pro-caspase-3 directly (type I cells) or via engagement of 
intrinsic pathway by cleaving Bid to tBid (type II cells). Additionally, Bid cleavage 
can be mediated by cathepsins, granzyme B, and c-Jun N-terminal kinase (JNK) 
[Cirman et al., 2004; Waterhouse et al., 2005; Deng et al., 2003]. 
 
Figure 1. General routes to caspase activation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subsequent translocation of tBid to the mitochondria initiates the intrinsic, 
mitochondria-mediated pathway, promoting release of mitochondrial proteins 
including holocytochrome c, AIF, Smac/Diablo and others. Apart from ligands of 
TNF family of plasma membrane death receptors, a plethora of compounds 
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converge on mitochondria to directly induce intrinsic pathway of cell death. In the 
cytosol, the normally benign holocytochrome c interacts with Apaf-1 (a mammalian 
homologue of Ced-4), stretching it out into more linear molecule that polymerizes 
upon binding ATP and recruits procaspase 9 via its N-terminal caspase-activation 
recruitment domain (CARD), forming a ~1 MDa protein complex of wheel-like 
seven-fold symmetry structure - apoptosome. According to the current model, 
activation of caspase 9 within apoptosome is achieved by dimerization of its 
monomers [Boatright and Salvesen, 2003], and subsequently triggers a self-
amplifying torrent proteolytic cascade that culminates in cell death (Fig. 1). 
Caspase 10, a close relative of caspase-8, may also directly activate pro-caspase-3 
and -7. Caspase-8 and -10 have overlapping cleavage preferences for several 
substrates, such as the kinases RIP and PAK2, and selective substrate cleavage 
specificities for others (e.g. Bid) [Fischer et al. 2005]. 
 
At cytosolic concentrations executioner caspases exist as preformed dimers, 
activated by cleavage carried out by an initiator caspase or occasionally by other 
proteases (e.g. granzyme B). Besides, these efficient cell demise effectors are 
controlled by inhibitor of apoptosis proteins (IAPs), binding and ubiquitinating the 
caspases for proteasomal degradation. These are additionally antagonized by two 
mitochondrial proteins SMAC/Diablo and Omi/HtrA2 (Fig. 1). 
 
Once activated, the executioner caspases orchestrate apoptosis through cleavage of a 
restricted array of cellular proteins, including lamin A, actin, Rb, ICAD, PARP, 
Gas2, gelsolin, PKC [Lavrik et al. 2005], leading to cell demise. Caspases 3 and 7 
have recently been identified as linchpins in regulation of mitochondrial uncoupling 
during apoptosis. Next, both initiator and executioner caspases can mediate cleavage 
of Bcl-2 family proteins [Cheng et al., 1997; Zhu et al., 2005; Gomez-Bougie et al. 
2005], not only inactivating MMP-inhibitory function of Bcl-2 or Bcl-XL, but also 
producing an MMP-promoting protein fragment [Hail et al. 2006]. Additionally, the 
activation of caspases may control the initial autophagic activity. Indeed, several 
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studies reported that inhibition of caspase activities induced autophagy-related 
sequestration of mitochondria and cell death [Djavaheri-Mergny et al. 2006]. 
Besides being involved in the regulation and execution of apoptosis, caspases have 
also a plethora of functions in other cell processes, such as cell differentiation, and 
negative or positive cell cycle control in B cells.   
2.2.3. Mitochondrion in cell death – the ultimate valve 
"We have tried to provide a map of the many roads to cellular ruin through the 
mitochondrial pathway; the ones most traveled in apoptotic cell death remain to be 
determined" 
Diana Spierings et al. 2005 
 
 
In aerobic cells mitochondria are organelles essential for respiration and oxidative 
energy production, forming a dynamic network that can serve as an effective power 
transmitter between remote parts of the cell, and are required for multiple 
biosynthetic pathways, marking them altogether as important for cell well-being and 
survival. Early evidence connecting mitochondria with apoptotic cell death 
conceived also that pro-apoptotic and pro-survival functions of these organelles are 
relatively separated [Newmeyer and Ferguson-Miller, 2003]. Recently, multiple 
mechanisms have been anticipated to explain mitochondrial function in cell death, 
including both mitochondrial physiological processes as well as passive release of 
apoptogenic proteins upon permeabilization of the outer mitochondrial membrane. 
The mitochondrial damage is considered as the "point-of-no-return" on the road to 
death programme. However, it is a stepwise, cumulative process not an abrupt 
phenomenon. Respiratory dysfunctions that occur in an early stage of apoptosis 
might potentially be overcome (by adding exogenous cytochrome c), but become 
irreversible with progressive damage to mitochondria over the time [van Loo et al 
2002]. It also appears that some cells survive cytochrome c release and without 
respiration (rhoo cells), providing the metabolic functions of mitochondria (amino 
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acid, heme and steroid metabolism, the membrane potential, protein import, integrity 
of inner membrane) are maintained. Additionally, the caspase-mediated 
amplification of the initial damage to mitochondria caused either by low levels of 
stress or in particular cell types may be required for cell death to proceed.  
 
Mitochondrial outer membrane permeabilization (MOMP)-mediated control of cell 
fate has been firmly established by several observations: 
1) MOMP generally precedes the signs of advanced apoptosis or necrosis, 
independent of the death-initiating pathway and irrespective of the cell type 
2) MOMP has better predictive value for cell death than other events, e.g. 
caspase activation 
3) MOMP can trigger an increase in mitochondrion-specific autophagy, denoted 
as "mitoptosis" or "mitophagy". Initially, it removes damaged and ROS-
overproducing mitochondria, but if excessive can result in cell death 
[Skulachev, 2006] 
4) A plethora of different apoptotic triggers (death domain receptors, 
chemotherapeutics, DNA-damaging agents, growth factor withdrawal, 
irradiation) converge on mitochondrial membranes. Lesions affecting distinct 
organelles within a cell, such as nuclei, the endoplasmic reticulum, or 
lysosomes, can trigger cell death through a final mitochondrial pathway. 
5) Anti-apoptotic members of Bcl-2 family physically interact with 
mitochondrial membrane proteins and inhibit cell death by virtue of MOMP 
prevention 
6) MOMP inhibition prevents or retards cell death; preservation of mitochondrial 
functions (e.g. by over-expressed Bcl-2 or the mitochondrion-targeted 
cytomegalovirus protein vMIA) during apoptosis can delay events associated 
with caspase activation such as loss of plasma membrane integrity or 
asymmetry 
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7) A large body of evidence suggest that MOMP constitutes a rate-limiting event 
in autophagic cell death 
8) cell-free systems have identified several mitochondrial proteins as rate-
limiting for the activation of catabolic hydrolases (caspases and nucleases) 
 
MOMP manifests at the level of the outer membrane (OM; allowing for the release 
of cytochrome c and other proteins), and/or inner membrane (IM) as a loss of the 
mitochondrial membrane potential (∆ψm). The latter one can occur before, during or 
after MOMP depending on the circumstances, and providing clues on the 
mechanism involved. 
  
 If the inner membrane participates in MOMP, a phenomenon known as 
permeability transition (PT) allows water and molecules up to 1.5kD to pass 
through, resulting in the equilibration of ions between the matrix and the cytoplasm. 
It is suggested that PT pore (PTP) consists of cyclophilin D (CypD) in the matrix, 
the adenine nucleotide translocator (ANT) protein in the inner membrane, associated 
with VDAC and the peripheral benzodiazepine receptor in the outer membrane, and 
possibly with some other proteins (e.g. creatinine kinase), or is formed by aggregates 
of misfolded and otherwise damaged integral membrane proteins [Kim et al. 2006, 
He and Lemasters 2002]. Sustained opening of PTP leads to ∆ψm loss and osmotic 
swelling of the matrix, often sufficient to break outer membrane and produce 
MOMP [Bouchier-Hayes et al. 2005, Waterhouse et al. 2002]. Importantly, many 
other events apart of PTP opening can induce ∆ψm loss, and its transient opening 
(trough flickering of the pore) can still sustain ∆ψm. Thus, PT-associated MOMP is 
strictly defined as a process that can be inhibited by ligands of putative PT pore 
constituents. The generality of PT as a primary mechanism for MOMP has been 
questioned, as swelling of mitochondrial matrix is not always observed in apoptotic 
cells, ∆ψm collapse does not always precede cytochrome c release and is often 
blocked by caspase inhibition, positing it is a secondary event and a consequence of, 
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not a reason for, cytochrome c release [Bouchier-Hayes et al. 2005, Von Ahsen et al. 
2000]. Still, the inner mitochondrial membrane components of PTP remain to be 
identified, and the absence of CypD or ANT may not preclude PTP opening [Forte 
and Bernardi, 2005], undermining the conclusions that PTP participates in cell death 
pathways only in response to a restricted set of stimuli. 
  
 It has also been proposed that mitochondrial hyperpolarization may cause 
MOMP, yet follow up studies suggest that although hyperpolarization does occur 
during apoptosis, it is not an absolute requirement for the release of cytochrome c 
[Waterhouse et al. 2002]. 
 
 Another mechanism does not imply involvement of PT, and considers MOMP 
as a process essentially intrinsic to the outer membrane and requiring members of 
the Bcl-2 family to promote or prevent the formation of pores. Briefly, according to 
the basic mechanisms suggested, they form membrane-spanning pores, interact with 
and regulate pre-existing channels such as PTP, and conceivably alter the membrane 
structure by interactions with membrane lipids. Although the significance of 
channel-forming activity of BH3-only and anti-apoptotic Bcl-2 family proteins 
under physiological conditions remains controversial, it is well substantiated that 
activation of Bax and Bak upon induction of apoptosis involves their 
oligomerization (Bax oligomers up to hexamers have been reported), integration into 
mitochondrial membrane (Bax), and formation of non-selective channels/lipidic 
pores, and in the absence of Bax and Bak (double knockouts) MOMP does not occur 
and cells are protected against several apoptotic but not necrotic death stimuli 
[Lindsten and Thompson, 2006]. In non-apoptotic cells Bax exists as a monomer 
either freely in the cytosol or loosely attached to the outer mitochondrial membrane. 
The activated Bax can be distinguished from its inactive form by exposition of 6A7 
epitope (an initial and reversible event that occurs prior to oligomerisation) upon 
conformational change within its N-terminus [Sharpe et al., 2004].  Some studies 
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indicate, however, that conformational changes in Bax and its subsequent 
translocation to mitochondria are insufficient for engaging its molecular function, 
and it is the Bax channel-forming activity that is required for apoptosis [Hetz et al., 
2005]. Alternatively, both Bax and Bak have been shown to interact with some 
resident mitochondrial proteins, such as previously mentioned components of the 
permeability transition pore VDAC1 and VDAC2, or adenine nucleotide 
translocator [Cheng et al., 2003]. Importantly, the Bax-VDAC interaction has 
promoting, whereas Bak-VDAC1 inhibiting, effects on MOMP. As recently 
demonstrated, Bax can also facilitate calcium-dependent PTP-opening [Schmidt-
Mende et al., 2006]. The changed conductance of existing in mitochondria channels 
could lead to mitochondrial swelling and the non-specific rupture of the MOM. 
Nevertheless, the action of pro-apoptotic members of Bcl-2 family on VDAC 
conformation is still controversial, as many groups have failed to validate the 
requirement of either VDAC or ANT for Bax killing, and no defects in recombinant 
Bax- or tBid-induced cytochrome c release were observed in cyclopholin D 
knockouts. Another model suggests that Bcl-2 family proteins can alter the 
composition or curvature of the mitochondrial lipid bilayer. Gong et al. have 
recently reported that the activity of tBid at mitochondria may be analogous to that 
of antibiotic polypeptides, which promote the outflow of bacterial cell contents 
through destabilization of the membrane bilayer structure [Gong et al., 2004]. 
Moreover, tBid-mediated lipid and cardiolipin redistribution could induce Bax to 
bind, intercalate and permeabilize the mitochondrial membrane. Indeed, the outer 
membrane permeabilization can be promoted by BH3/Bax interaction, and the 
process reportedly requires cardiolipin [Kagan et al., 2005]. 
 
 Recently, a hybrid model has been proposed [De Giorgi et al., 2002], asserting 
that PTP opening may not lead to mitochondrial swelling but promotes perforation 
of the outer membrane trough the recruitment and activation of Bax. Other proteins 
of the OM could also modulate the function of Bcl-2 related proteins. An unresolved 
 27
but intriguing issue is also the involvement of mitochondrial fission and fusion-
related proteins, such as Drp1 and Mfn2 [Youle and Karbowski 2005, Sugioka et al. 
2004, Karbowski et al. 2002]. Although clearly an extensive mitochondrial fission is 
associated with apoptosis, it is disputable whether this phenomenon contributes to 
cytochrome c efflux.  
 
Finally, recent evidence suggests that ceramide and sphingosine are able to form 
channels in mitochondrial membranes [Otera et al. 2005]. Nonetheless, sphingosine 
channels, unlike ceramide ones, are not large enough to allow the passage of pro-
apoptotic proteins from the intermembrane space of mitochondria to the cytoplasm 
[Siskind et al. 2005]. 
 
It is currently suggested that as much as 90% of the mitochondrial cytochrome c is 
kept within the folds of inner membrane (i.e. cristae) - relatively closed 
compartments with movement of molecules from within restricted by the diameter 
of the openings (i.e. cristae junctions). Thus, in addition to Bax/Bak –dependent 
permeabilization of the mitochondrial outer membrane, extensive remodelling of the 
mitochondrial inner membrane also appears to be required for efficient translocation 
of cytochrome c into cytosol. Scorrano and De Strooper have proposed a model 
whereby formation of oligomers between OPA1 bound to the inner membrane and 
shorter OPA1 isoforms located within intermembrane space restricts the passage of 
cytochrome c, and other cristae proteins, into the mitochondrial intermembrane 
space. Upon proapoptotic stimuli, OPA1 oligomers become destabilized, which 
leads to remodelling of IM and release of cytochrome c contained within cristae 
[Delivani and Martin, 2006]. 
 
In any case, MOMP can result in cell destruction through four, not mutually 
exclusive, mechanisms [Spierings et al., 2005; Ricci et al., 2003]:  
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1) Release of death-promoting molecules involved in the activation of caspases 
 (holocytochrome c, Smac/DIABLO, Omi/HtrA2) and the pro-apoptotic factors 
 involved in caspase-independent cell death (AIF, endonuclease G). 
 
The mitochondrial intermembrane space (IMS) contains several death-promoting 
proteins. As mentioned above, the release of holocytochrome c mediates the 
allosteric activation and hepta-oligomerization of Apaf-1, and subsequent 
recruitment and activation of caspase-9. Importantly, recent studies by Tang and 
co-workers indicate that the proapoptotic properties of cytochrome c can be 
neutralized by electrostatic interactions with nucleotides, preventing its 
interaction with Apaf-1. Smac/DIABLO and Omi/HtrA2 both have IAP-binding 
N-termini. AIF and EndoG, once in the cytosol, are able to translocate to the 
nucleus and promote DNA-fragmentation and caspase-independent cell death. 
Additionally, depending on the cell type, mitochondrial intermembrane space 
contains procaspases, and caspases 3 and 7 may amplify cytochrome c release 
during apoptosis [Adrain and Martin, 2006].  
It is still debated whether mitochondrial IMS proteins are co-released during 
apoptosis. As elegantly showed by Uren and co-workers, cytochrome c, 
Smac/DIABLO and Omi/HtrA2 translocate from the intermembrane space, 
whereas  AIF and EndoG remain tethered to the inner membrane [Uren et al., 
2005]. To add even more complexity, the pro-apoptotic proteins released on 
MOMP can be further regulated following their translocation; AIF and EndoG 
activity can be blocked by Hsp70 [Kalinowska et al., 2005], whereas 
Apollon/BRUCE binds and ubiquitinlates SMAC/DIABLO and HtrA2, marking 
them for proteasomal degradation [Sekine et al., 2005].  
 
 
2)  Irreparable loss of mitochondrial functions essential for cell survival 
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Cytochrome c transfers electrons between complex III (cytochrome bc1) and 
complex IV (cytochrome c oxidase) of the respiratory chain. Although some 
cells (rhoº cells) can survive cytochrome c release, dissipation of the 
mitochondrial transmembrane potential (∆ψm) has in general lethal 
consequences. Loss of ∆ψm is indicative of abnormal inner membrane 
permeability, and is expected to induce a cessation of the import of most proteins 
synthesized in the cytosol, release of Ca2+ and glutathione from the 
mitochondrial matrix, uncoupling of oxidative phosphorylation with cessation of 
ATP synthesis, oxidation of NAD(P)H2 and glutathione, and finally hyper-
production of superoxide anion by the uncoupled respiratory chain. In addition, a 
decreased rate of electron transfer will result in decreased consumption of 
mitochondrial pyruvate, and its conversion into lactate, which in turn leads to 
cytoplasmic acidification and cell death. 
 
3)  Induction of reactive oxygen species (ROS) 
 Mitochondria are the major cellular source of ROS. Excess of ROS may react 
with and modify cellular macromolecules and critical cellular targets (lipid 
peroxidation, calcium mobilization, mitochondrial permeability transition, ATP 
depletion, protein oxidation, loss of electron transport, DNA damage), promoting 
cell death. Interestingly, under some conditions ROS can also stimulate 
protective mechanisms, such as NF-κB activation or caspase inhibition, blocking 
cell death [Ricci et al., 2003]. 
 
4) Induction of "mitoptosis" 
Modest induction of MMP, below the threshold required for induction of 
apoptosis, results in the selective sequestration of mitochondria in 
autophagosomes. Likewise, NGF (nerve cell growth factor)-starved neurons 
cultured in the presence of caspase inhibitors manifest MMP and subsequently 
autophagic removal of mitochondria, resulting in cell death presumably as a sign 
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of metabolic insufficiency. This mitochondrion-specific autophagy is denoted as 
mitoptosis. 
 
2.3. THE BCL-2 RIDDLE 
 
2.3.1. Bcl-2 family members 
The Bcl-2 family of proteins is the crucial integrator of cell survival and cell death 
signals. More than 30 members of the family have been identified over the past 
years. In mammalian cells the pro-survival members of the family (Bcl-2, Bcl-XL, 
Bcl-w, Mcl-1, and A1) are functionally opposed by two pro-apoptotic groups: Bax-
like proteins (Bax, Bak and Bok) that share a high degree of structural similarity to 
pro-survival Bcl-2-like proteins, and the BH3-only proteins (e.g. Bad, Bim, Bmf, 
Noxa, PUMA) that display sequence conservation only in the amphipathic α-helical 
BH3 region (Fig.2). Recently, novel members of the family have been described, 
including Bcl-GL, Bfk and Bcl-rambo, Bcl-B, or Bcl-2/adenovirus E1B 19 kDa-
interacting protein 3 (BNIP3)  [Kataoka et al., 2001; Coultas et al., 2003; Ke et al. 
2001]. 
 
Most members of the clan possess a hydrophobic C-terminal segment, facilitating 
their interaction with the endoplasmatic reticulum(ER), nuclear envelope and the 
outer mitochondrial membrane, where they reside or congregate during apoptosis.  
Moreover, the members of the family can be found in the cytosol or being bound to 
microtubules. The control over the subcellular localizations of different Bcl-2 
proteins occurs through heterodimerisation, phosphorylation, proteolysis, or 
interaction with FK-506-binding protein 38 (FKBP38) [Kang et al., 2005; Shirane 
and Nakayama, 2003; Kaufmann et al., 2004].  
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Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
2.3.2. Cellular role of Bcl-2 family proteins 
 
I have recently reviewed the role of Bcl-2 proteins as key regulators of 
mitochondrial membrane permeability [Skommer et al., 2006], which is also shortly 
summarized above. However, there is a burgeoning knowledge on ancillary 
functions of Bcl-2 proteins that determine cell fate, as summarized below: 
 
1) Bid is phosphorylated in ATM-dependent manner after DNA damage and 
translocates into the nucleus. The phosporylated Bid is required for the cell cycle 
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arrest in S phase and thus may play a pro-survival role [Kamer et al., 2005; 
Zinkel et al., 2005; Gross 2006] 
2) BNIP3 is a linchpin in ceramide- and arsenic trioxide-induced autophagic cell 
death 
3) Apart from regulatory influence of Bcl-2 on mitochondria, the protein can exert 
protective effects also when expressed at the endoplasmic reticulum (ER), 
through regulation of caspase activation, calcium homeostasis or Bax activation 
[Rudner et al., 2002].   
4) ER-targeted Bcl-2 inhibits autophagy and caspase-independent cell death, 
conceivably through a direct interaction with the evolutionary conserved 
autophagy protein Beclin 1, providing a rheostat that maintains autophagy at 
attuned with cell survival levels [Pattingre et al., 2005] 
5) Approximately 10-15% of Bax or Bak is also localized at the endoplasmic 
reticulum, where they regulate the unfolded protein response (UPR) and steady-
state ER calcium homeostasis. 
6) Bik reportedly regulates calcium release from ER upstream of Bax and Bak 
7) Depending on cellular context, Bcl-2 protein may modify subcellular localisation 
of Apaf-1 [Ruiz-Vela et al., 2001] 
8) Bcl-2 proteins can regulate cell cycle; For instance, Bcl-2 and Bcl-XL are 
antiproliferative by facilitating G0, whereas Bax accelerates S-phase progression 
[Zinkel et al. 2006]. 
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2.3.4. Outline of current approaches to inhibit Bcl-2 
Overexpression of Bcl-2 and/or Bcl-XL or loss of Bak and/or Bax function has been 
linked to acquired resistance of tumours to radiation and/or chemotherapy. The 
strategies to overcome the cytoprotective effects of Bcl-2 and related anti-apoptotic 
proteins in cancer and leukemia include shutting off gene transcription, inducing 
mRNA degradation with antisense oligonucleotides (ASOs) or mRNA decay with 
drugs down-regulating or inactivating nucleolin [Otake et al. 2004, Otake et al. 
2005], directly attacking the proteins with small-molecule drugs, and bringing into 
play endogenous antagonists of anti-apoptotic Bcl-2 family proteins. There are also 
strategies to increase the amount of pro-apoptotic Bcl-2 members within cells, 
including adenoviral administration of Bak, Bax or Bik [Lowe et al., 2001; 
Naumann et al. 2003; Shinoura and Hamada, 2003]. 
 
Multiple drugs have been shown to regulate the BCL2 gene expression, including 
some synthetic retinoids, histone deacetylases inhibitors, peroxisome-proliferator-
activated receptor γ (PPARγ)-modulating drugs, or curcumin (see below). The most 
common drug targeting BCL-2 mRNA - G3139 (oblimersen sodium) - has shown 
promising bioactivity in some, but not all studies. Among the major disadvantages 
of this approach are slow degradation rate of the Bcl-2 protein (which necessitates a 
prolonged suppression of mRNA accumulation) and G3139-induced inflammatory 
responses.  
 
Drugs attacking directly Bcl-2 proteins are the alternative that is currently being 
extensively tested in pre- and clinical trials [Tzung et al. 2001]. Since pro-apoptotic 
Bcl-2 family members dock into the BH1-BH2 groove of pro-survival members via 
their BH3 domain, it has been suggested that BH3 mimetics, developed trough 
rational design or functional screening, could promote apoptosis in cancer cells. 
Indeed, the pro-apoptotic action of a variety of BH3 peptides has been reported in 
cancer cell lines, and upon improvement of pharmacological properties (e.g. 
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hydrocarbon stapling to stabilize the alpha-helical BH3 peptide derived from BH3-
only protein BID, conjugation with N-(2-hydroxypropyl)methacrylamide (HPMA)) 
in mouse xenograft models [Walensky et al., 2004; Oman et al. in press].   
Considering that BH3 only proteins differ with respect to their binding preferences, 
the respective mimetics of BH3 domains may target multiple pro-survival members 
but potentially could also be designed as more selective antagonists. Clinical 
opportunities emerging from such approach are yet to be learnt.   
 
Table 1. Exemplary small molecule antagonists of pro-survival Bcl-2 family 
proteins [Shore and Viallet, 2005; Mohammad et al., 2005; Oliver et al., 2004; 
Wang et al., 2000; Reiners and Kessel, 2005; Pei et al., 2004; Roa et al., 2005; Ray 
et al., 2005; Hao et al., 2004; Shoemaker et al., 2006].  
 
Compound Cell type  Stage 
 
gossypol 
pancreatic cancer cells, colon 
carcinoma cells, head and neck 
squamous cell carcinomas cells, 
diffuse large cell lymphoma cells, 
prostate cancer cells 
 
phase 2 
HA14-1 colon cancer cells, myeloma cells, 
myelomonocytic leukemia cells, 
lymphoma cells 
 
preclinical 
BH3I-1 and -2 non-small cell lung cancer cells, 
prostate cancer cells, 
lymphoblastic leukemia cells 
 
preclinical 
ABT-737 small cell lung carcinoma, 
lymphoma cells 
preclinical 
 
GX015-070 
cell lines derived from cervical, 
colon, prostate, and mammary 
carcinomas, melanoma cells 
 
Phase 1/2 in progress 
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2.4. CURCUMIN 
 
“Nothing will benefit human health and increase the chances for survival of life on 
Earth as much as the evolution to a vegetarian diet” 
Albert Einstein 
 
Given the long natural history of follicular lymphoma, survival benefits must be 
watchfully balanced with quality of life. Indeed, severe side effects invoked by most 
of anticancer agents are the important impediment to the therapy of FL and other 
malignant disorders. Not surprisingly thus the idea of conquering cancer with natural 
compounds exerting minimal or no toxicity in humans has been gaining momentum. 
As the ancient Indian scripture Ayurveda, developed through daily life experiences 
with the mutual relationship between mankind and nature, is being translated into 
English, Spanish, German, French and other languages, it has become a rich source 
of inspiration in search for pharmacologically safe anticancer drugs.  
Curcumin (diferuloylmethane) is a major yellow pigment extracted from the spice 
turmeric, which is isolated from a tropical plant native to southern and southeastern 
Asia - Curcuma longa. Curcumin´s properties as a colouring and flavouring agent 
have led to its widely use as a dietary additive in a variety of foods, including 
mustard and other species, gelatins, puddings, sorbets, soups, margarine, and even 
alcoholic and non-alcoholic beverages. The maximum dietary consumption of 
turmeric (1.5g per person per day) is being noted in certain South East Asian 
communities, but its usage as a colouring, food preservative and flavouring agent is 
global - over 2400 metric tons of turmeric are imported annually into the USA for 
consumer use [Sharma et al. 2005]. Commercial curcumin contains three major 
components: curcumin I (Fig. 3), demethoxycurcumin (curcumin II), and 
bisdemethoxycurcumin (curcumin III), which are together referred to as 
curcuminoids.  
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Figure 3. Structure of curcumin I 
 
 
 
 
 
Curcumin has been used in Asian medicine since the second millenium BC to treat 
biliary disorders, anorexia, cough, diabetic wounds, hepatic disorders, rheumatism, 
and sinusitis [Jain and DeFilipps 1991]. The chemopreventive and anticancer effects 
of this plant polyphenol are widely recognized and have been a subject of several 
excellent reviews [Duvoix et al. 2005, Aggarwal el al. 2003, Sharma et al. 2005]. Of 
utmost importance, the outstanding safety records from phase I/II clinical trials, 
supported by a long history of curcumin´s consumption as a dietary additive without 
any side effects, are supportive for its clinical application.  
 
2.4.1. Targeting of apoptotic pathways by curcumin 
Cancer is a disorder of hyperproliferation and/or excessive survival that tends to 
metastasize into the vital organs through invasion followed by angiogenesis and 
distant metastasis. Although the order of acquisition of underlying changes may 
differ depending on tumour type and even between cells within the tumour, in 
general terms malignant progression can be divided into several discernible stages. 
Accordingly, Figure 4 summarizes selected in vitro and/or in vivo activities of 
curcumin in relation to the hallmarks of cancer in a step-wise mode. Such 
pleiotropic effects of curcumin are mediated by effects on a host of cell signalling 
factors, including AP-1 transcription factor, c-Myc, Egr-1, IκB kinase, NF-κB, 
protein kinase C, epidermal growth factor receptor tyrosine kinase, c-Jun N terminal 
kinase, protein tyrosine kinases, protein serine/threonine kinases, or bcl-2-family 
proteins (see below) [Chen et al. 2004, Aggarwal et al. 2003, Aggarwal et al. 2005]. 
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Figure 4 Cancer hallmarks versus action of curcumin. * - described in more detail 
below. 
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Ample evidence exists to show the induction of apoptosis upon curcumin treatment 
in diverse tumour cells, including B-cell and T-cell leukemia, B-cell lymphoma, 
colon carcinoma and breast carcinoma cells. Mostly, curcumin sequentially induces 
activation of caspase-8, Bid cleavage, mitochondrial breach, PTP opening, release of 
cytochrome c, activation of caspase-9 and -3, and cleavage of PARP and ICAD. 
Translocation of AIF to the nucleus has also been reported. Additionally, curcumin 
induced apoptosis-like pathway that lacked the involvement of mitochondrial 
membrane depolarization and was not dependent on caspase activity in human 
lymphoblastoid T (Jurkat) cells [Piwocka et al. 1999]. Various mechanisms account 
for the pro-apoptotic effects of curcumin (Fig. 5). Inhibition of NF-κB translocation, 
originally reported by Singh and Aggarwal [1995], has been observed in multiple 
cell types, such as colon, gastric, squamous epithelial tumor, B-cell lymphoma, 
chronic lymphocytic leukemia [Everett et al. 2006] and multiple myeloma cell lines 
and/or primary cells 8 [Bharti et al. 2003], and may be due to a direct effect of 
curcumin on NIK, IKKα, or IKKβ kinases [Plummer et al. 1999]. That curcumin 
exerts apoptosis via p53-dependent pathway was shown in mammary epithelial 
carcinoma cells [Choudhuri et al., 2005], neuroblastoma cell lines [Liontas and 
Yeger, 2004], and colon cancer cells. Down-regulation of antiapoptotic proteins 
(Bcl-2, Bcl-XL, IAP1, IAP2, XIAP) represents another mechanism of curcumin-
triggered apoptosis. Bax, but not Bak, has been suggested as a critical regulator of 
curcumin-induced apoptosis in human colon cancer cells [Rashmi et al., 2005]. 
Accordingly, several approaches to augment curcumin-based therapy have been 
proposed, including silencing of Hsp70, Bcl-XL, or Ku70 [Rashmi et al., 2004], or 
over-expression of Smac [Rashmi et al., 2005].  
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Figure 5 Commonly reported curcumin´s targets within the apoptotic pathway of 
cell death 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relatively limited data are available on the effects of curucmin on chemtotherapy-
induced killing of cancer cells. Somasundaram and co-workers reported that 
curcumin inhibited camptothecin-, mechlorethamine-, and doxorubicin-induced 
apoptosis both in vitro and in vivo, and suggested curcumin to generally hamper 
apoptosis induced by ROS-generating and JNK-activating chemotherapeutics 
[Somasundaram et al. 2002]. In another study however, pre-treatment with curcumin 
was shown to enhance cytotoxicity of vinorelbine in vitro in lung squamous cell 
carcinoma cell line [Sen et al. 2005]. In hepatic cancer cell line the combination of 
curcumin and cisplatin resulted in synergistic antitumour activity, whereas the 
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effects of curcumin and doxorubicin were additive [Notarbartolo et al. 2005]. 
Moreover, curcumin potentiated taxol-induced apoptosis in HeLa cells, an effect at 
least partially related to curcumin-induced down-regulation of NF-κB and 
serine/threonine kinase Akt pathways [Bava et al. 2005]. Both the potential of 
cooperative tumour cell killing and danger of curcumin-mediated decrease in 
anticancer drug efficacy have yet to be assessed in the clinic. 
 
2.4.2. Successes and failures of curcumin in clinical trials 
The side effects following administration of curcumin are extremely rare. Abnormal 
liver tests and transient hypotension have been reported in rats and dogs, 
respectively, but not in humans. When taken without food curcuminoids may cause 
gastritis and peptic ulcer, and thus it is advisable to take curcumin supplements with 
meals or postprandial.  
 
The pharmacokinetics of curcumin in humans has been analyzed: 
 
- in patients with advanced colorectal cancer; Administration of curcumin at 36-180 
mg/day for up to 4 months was well tolerated, but curcumin was recovered only 
from feces, not blood or urine [Sharma et al. 2001]. In a subsequent phase I study 
in 15 patients, a curcuminoid formulation was consumed orally for up to 4 months, 
equating to curcumin doses between 0.45 and 3.6 g/day [Sharma et al. 2004]. 
Daily dose of 3.6 g has been later on shown amenable for achievement of 
pharmacologically efficacious levels of curcumin in the colorectum [Garcea et al. 
2005].   
 
- in patients with one of the following:  urinary bladder cancer, arsenic Bowen´s 
disease of the skin, uterine cervical intraepithelial neoplasm, oral leucoplakia, 
intestinal neoplasia of the stomach [Cheng et al. 2001]; Curcumin was given orally 
for 3 months, at doses ranging from 0.5 to 12 g/day. No treatment-related toxicity 
was noted at doses up to 8 g/day. The serum concentration peaked at 1-2 h after 
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oral intake, declining gradually over the next 12 h. The 8 g/day dose resulted in a 
serum concentration of 1.77±0.87 µM 
 
- in patients with chronic anterior uveitis [Lal et al. ] 
 
- in patients suffering from idiopathic inflammatory orbital pseudotumors [Lal et al. 
2000]; Curcumin was administered orally at dose of 1125 mg/day for 6-22 
months. 4 out of 5 patients that completed the study completely recovered. 
- in patients with ulcerative proctitis (n= 5) and Crohn's disease (n=5) [Holt et al. 
2005]; Curcumin was administered orally at dose of 1.08 g/day for 1 month 
followed by 5.76 g/day for next 2 months.  
 
- in healthy volunteers, curcumin was administered orally at dose of 50-200 mg, 
without toxicity and detectable systemic bioavailability [Sharma et al. 2005] 
  
Although encouraging, the clinical studies clearly demonstrate that orally 
administered curcumin has poor bioavailability and may undergo intestinal 
metabolism. Moreover, curcumin is highly hydrophobic and thus cannot be 
administered systematically. Fortunately, several approaches have already been 
suggested to improve curcumin´s bioavailability and to circumvent the difficulty 
with intravenous dosing: 
- liposome encapsulation [Li et al., 2005] 
- curcumin biojonjugates [Kumar et al., 2000] 
- co-administration with piperine [Shoba et al., 1998] 
- prolonged release biodegradable microspheres encapsulation [Kumar et al., 2002] 
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3 AIMS OF THE STUDY 
 
The study was undertaken to investigate cellular and molecular mechanisms 
underlying apoptosis triggered by selected chemical and natural compounds in 
human follicular lymphoma B cell lines. 
 
 
The specific questions/aims of the study were: 
 
 
To elucidate the temporal and quantitative relationship between mitochondrial 
membrane depolarization and caspase activation in HA14-1-induced apoptosis, and 
cell cycle specificity of HA14-1-triggered apoptosis. (I) 
 
Does the natural dietary additive curcumin trigger apoptotic response in Bcl-2 over-
expressing FL cell lines and how their sensitivity to curcumin can be enhanced? 
What are the mechanisms behind curcumin-evoked apoptosis in this model? (II) 
 
To identify gene expression reprogramming relevant for the pathophysiology and 
therapy of follicular lymphoma in curcumin-treated HF4.9 cells using DNA 
microarray technology. (III) 
 
To determine whether CXCR4 is a component down-regulated specifically during 
curcumin-induced cell demise, or is a general apoptosis/cell death associated 
phenomenon. (IV) 
 
 43
4 MATERIALS AND METHODS 
"Cytometry is easy. Biology is hard." 
Howard Shapiro 
4.1. Cell lines and culturing (I-IV) 
The experiments have been performed on three follicular lymphoma cell lines 
HF1A3, HF4.9 and HF28RA [Eray et al. 2003]. Cells were cultured in RPMI 1640 
medium (Cambrex, Verviers, Belgium) supplemented with 5% heat-inactivated FCS 
(EuroClone, Pero, Italy), 2 mM L-glutamine (Fluka Chemie, Buch, Switzerland), 
200 µg/µl streptomycin (Sigma, St. Louis, MO, USA), 240 IU/ml penicillin (Orion, 
Espoo, Finland), 10 mM HEPES buffer (Cambrex), 0.1 mM NAA (Cambrex), 1 mM 
Na-pyruvate (Cambrex) and 20 µM 2-mercaptoethanol (Fluka Chemie) at 37˚C in a 
5% CO2 humidified atmosphere. 
4.2. Cell treatment experiments 
 
In Publication I, HF4.9 cells were treated with 5µM HA14-1 (Alexis Biochemicals) 
for 0-4h at 15 min intervals.  Pan caspase inhibitor zVAD-fmk (100µM) was added 
2 h before HA14-1 administration. 
 
In Publication II, freshly dissolved curcumin was added directly to cell cultures, 
and all experiments were performed in the dark due to possible degradation products 
of the polyphenol. Cell death was also induced in HF1A3 cells by CD95 cross-
linking with anti-Fas antibody (100ng/ml; clone CH11; Upstate, NY, USA). 
Ascorbic acid was procured from Sigma. PD150606 (inhibitor of calpains), CA-074-
Me and zFA-fmk (cathepsin B inhibitors), and ALNN (calpain I inhibitor) were 
generously provided by Dr Michael Courtney (AIV Institute, Kuopio, Finland). Pan-
caspase inhibitor zVAD-fmk was added at various concentrations (0-100µM) 2h 
before exposition to curcumin. All compounds were diluted in cell culture medium 
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to working stock immediately before use. No alterations in growth variables were 
observed in vehicle controls. 
 
In Publication III, HF4.9 cells were treated with 15 µM curcumin for 0-36h. 
Alternatively, HF4.9 cells were pre-treated for 1h with 250 nM CsA (cyclophilin D 
inhibitor), followed by administration of curcumin (10 and 15 µM) for 24h. 
Additionally, HF1A3, HF4.9, and HF28RA cells were exposed to AMD3100 
(Sigma), a selective CXCR4 antagonist, alone or in media devoted of serum. 
 
In Publication IV, HF4.9 cells were left unstimulated or treated with 2.5µM 
doxorubicin (a gift from the Kuopio University Hospital), 5nM vincristine (a gift 
from the Kuopio University Hospital), 7.5µM HA14-1 (Alexis Biochemicals), or 
100ng/ml brefeldin A (BFA). HF1A3 cells were treated with CD95 cross-linking 
antibody. To assess the effect of oncotic stimuli on CXCR4 expression, HF1A3 cells 
were also exposed to 3% H2O2 for 15min. 
  
4.3. Cell proliferation and viability assays 
4.3.1. [3H]-Thymidine incorporation assay (II) 
The anti-proliferative effects of curcumin were monitored by thymidine 
incorporation assay. Cells (1x106 cells/ml) were treated in flat-bottom, 96-well 
(200µl/well) plates with different concentrations of curcumin (1-50 µM) in complete 
medium for 20 h before adding 1µCi/ml [methyl-3H]-thymidine for an additional 4 h 
at 37˚C. The incorporated radioactive thymidine was quantified by scintillation 
counting with Microbeta counter (Perkin Elmer, MA, USA). All determinations 
were made in triplicate. 
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4.3.2. Trypan blue staining (II) 
Cell viability/growth was also examined using the trypan blue exclusion method. 
After incubation with curcumin, the cells were mixed with an equal volume of PBS 
containing 0.4% (w/v) trypan blue dye, and counted manually using a 
hemocytometer. Trypan blue negative cells were scored.  
 
4.4. Apoptosis detection 
4.5.1. Morphological assessment (II) 
A cell that is undergoing apoptosis demonstrates nuclear condensation and DNA 
fragmentation. For visualization of nuclear alterations in curcumin-treated cells, 
cells were rinsed with cell culture media and stained with Hoechst 33342 for 20 min 
at room temperature. Imaging was carried out with a cooled Apogee KX85 CCD 
(publication I) and IX70 Olympus (publication III) microscope with appropriate 
filter cubes. Images were assembled into figures using Adobe Photoshop. 
4.5.2. Quantification of fractional DNA content (II) 
Propidium iodide staining was used for quantification of cells with increased sub-G1 
content. At the end of experiment, cells were harvested, washed twice with PBS and 
fixed in 70% EtOH at +4°C overnight. Next, cells were treated with RNase 
(10µg/ml; Sigma) for 2h at 56°C followed by 1h incubation at 37°C with 5µg/ml PI 
(Sigma). Subsequently, cells were analyzed on FACScan flow cytometer (Becton 
Dickinson) running under Cell Quest software, with 10000 events acquired per 
sample. Data analysis was performed with Summit v3.1 software (Dako 
Cytomation, Fort Collins, CO, USA). 
4.5.3. Conformational DNA/RNA changes (II, III, IV) 
The vital stain SYTO16 (Molecular Probes, Eugene, OR, USA) allows the accurate 
estimation of the number of viable cells, and in combination with permeability 
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marker PI (Sigma) has been used to identify an early stage of apoptosis. The 
specificity of SYTO16 to detect apoptotic changes in FL cells was confirmed by the 
lack of SYTO16dim/PI- events in hyperthermia-induced (56˚C for 5 min) or H2O2-
induced (0.3% for 4h) oncosis. Upon staining, cells were analyzed on FACScan flow 
cytometer (Becton Dickinson, San Jose, CA, USA) running under CellQuest 
software (Becton Dickinson), with 10000 events acquired per sample. Data were 
subsequently analyzed using Summit v3.1 software (Dako Cytomation, Fort Collins, 
CO, USA). 
 
4.5.4. Cell membrane permeabilization (II) 
For identification of early cell membrane permeabilization, cells were stained with 
YO-PRO 1 (Molecular Probes), a 374Da cation. Cells with early cell membrane 
permeabilization are stained only with YO-PRO 1, whereas those in late stages of 
apoptosis and necrotic cells are characterized by more pronounced loss in cell 
membrane integrity, and are thus stained with both YO-PRO 1 and PI. Briefly, cells 
were harvested, washed with PBS, incubated with 250nM YO-PRO 1 and 5µg PI for 
20 min at RT in darkness, and analyzed on FACScan flow cytometer (Becton 
Dickinson). The nuclear morphology of PI+ cells was investigated to determine 
whether it is necrosis or advanced apoptosis (postapoptotic necrosis). 
4.5.5. Mitochondrial membrane potential depolarisation (I, II) 
Lipophilic cations, including JC-1, TMRM, CMXRos and others, accumulate in the 
mitochondrial matrix, driven by the electrochemical gradient. Herein, loss of 
mitochondrial membrane potential was assessed using TMRM (Molecular Probes) in 
combination with FLICA and cell membrane permeability marker (publication I, for 
a detailed description of the procedure see below), or in combination with 
permeability marker alone (publication II).  
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4.5.6. Cytochrome c release (II) 
Preparation of mitochondria or cytosolic extracts from control and curcumin-treated 
cells (2x107) was performed using the ApoAlert Cell Fractionation kit (BD 
Biosciences) according to the manufacturer instructions. Equal loading of 
mitochondria and cytosol was assessed by immunobloting with mouse anti-
cytochrome oxidase subunit IV (COX4) and by Poncaeu S staining, respectively. 
 
4.5.7. Caspase activation (I, II, IV) 
Most often, activation of caspases is assayed indirectly by testing whether their 
inhibitors prevent particular apoptotic events (publication I). Commonly, the 
activation of caspases is detected via immunoblotting techniques using specific 
antibodies against caspases, or against cleavage products, such as poly(ADP-ribose) 
polymerase (PARP), (publication II and IV). Another common approach is to 
employ fluorochrome substrates which become fluorescent upon cleavage by the 
caspase, or FLICA - a cell permeable and non-toxic FLuorochrome Inhibitor of 
CAspases. When added to a population of cells, FLICA probe enters each cell and 
covalently binds to a reactive cysteine residue that resides on the large subunit of the 
active caspase heterodimer. Because FLICA becomes covalently bound to the 
enzyme, it is retained within the cell, whereas uncoupled FLICA diffuses out of the 
cell and is washed away. Thus, the remaining fluorescence signal can be considered 
as a direct measure of the number of active caspases present in the cell (publication 
I and II). 
 
4.5.8. Multiparametric flow cytometry assays (I) 
4.5.8.1. Triplicate TMRM / FLICA / 7-AAD staining 
In publication I the multivariate assay analogical to one used by Pozarowski et al. 
[Pozarowski et al. 2003] was applied. The approach allows simultaneous tracking of 
mitochondrial membrane depolarisation (by TMRM), caspase activation (by FLICA) 
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and cell membrane permeability (by 7-AAD). After the challenge cells were 
harvested, resuspended in 100µl of fresh medium, followed by staining with FLICA 
(Immunochemistry Technologies, LLC) according to the manufacturer's instructions 
(1h at 37°C). Next, cells were harvested, washed twice with ice-cold PBS, and 
stained with 150 nM TMRM (Molecular Probes) for 15 min at 37°C. Finally, cells 
were stained with 7-AAD (5µg/ml; Molecular Probes) for 3-5 minutes at RT. All 
staining procedures were performed in the dark.  
 
4.5.8.2. Detection of cell cycle specificity of apoptosis 
In publication I, FL cells were exposed to HA14-1 at dose and for the time 
indicated, followed by and staining with FAM-VAD-FMK for 1h at 37°C. Next, 
cells were fixed in ethanol for at least 2 h at -20°C, stained with propidium iodide 
(PI, 5 µg/ml; Sigma) in the presence of RNase (20µg/ml; Sigma) for 1h at 37°C, and 
immediately analyzed on FACScan flow cytometer (Becton Dickinson).  
 
4.6. Cell cycle analysis 
Cell cycle alterations induced by curcumin (unpublished data) were studied by flow 
cytometry analysis. Cells were plated at the density of 1 x 106 and cultured for 24 h 
in media alone, or treated with curcumin. Cells were harvested and washed twice 
with PBS, fixed with 70% ethanol overnight, pre-treated with 10µg/ml RNase 
(Sigma) for 1h, followed by staining with PI (5 µg/ml; Sigma) for 2h. The cell cycle 
profile was determined with FACScan flow cytometer, running under CellQuest 
software, with subsequent analysis using Summit software. 
 
4.7. Lysosomal membrane permeabilization (II) 
In publication II, cells were assessed for lysosomal stability following treatment 
with curcumin using the acridine orange (AO) uptake method. Cell were stained 
after the challenge with curcumin, and analyzed immediately on FACScan flow 
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cytometer. AO is a lysosomotropic base and a metachromatic fluorochrome 
exhibiting red fluorescence when highly concentrated (as is the case in intact 
lysosomes where AO is retained in its charged form - AOH+). When outside the 
lysosomes, AO exhibits green fluorescence. The lysosomal burst was further 
evaluated by staining with another acidophilic dye - LysoTracker Red (Molecular 
Probes), followed by fluorescent microscopy analysis. The loss of punctuate staining 
of LysoTracker red indicates disruption of acidic vacuoles. 
4.8. Detection of reactive oxygen species (ROS) (II) 
The intracellular ROS generation can be assessed using dihydroethidine probe 
(DHE), which is oxidized by superoxide anion to become ethidium bromide (EthBr) 
emitting red fluorescence, or by dihydrofluorescein diacetate (H2DCFDA). After the 
challenge with HA14-1 or curcumin, cells were harvested, washed with PBS, and 
stained with 2.5µM DHE for 20min at RT. For H2DCFDA staining, cells were 
loaded with 1 µM H2DCFDA for 20-30 min at 37˚C prior to cell stimulation. 
4.9. Cell surface staining (III) 
The cell surface expression of CXCR4 in FL cell lines was assessed using FITC-
conjugated mouse monoclonal anti-human CXCR4 antibody (clone 12G5; R&D 
Systems). Briefly, 0.5x106 cells were stained with 20µl of anti-CXCR4 Ab, or FITC-
conjugated IgG1 isotype-control (BD Biosciences, San Diego, CA, USA), for 30min 
at RT. After staining cells were analyzed by flow cytometry (FACScan, Becton 
Dickinson). 
4.10. Immunoblotting (II, III, IV) 
Samples prepared in 1x Laemmli buffer (62.5 mM Tris-HCl, pH 6.8, 1% SDS (w/v), 
5% 2-mercaptoethanol, 10% glycerol (v/v), and 0.001% bromophenol blue (w/v)) 
were resolved by 10-15% SDS-PAGE and transferred onto nitrocellulose. 
Nitrocellulose was blocked with 5% milk in TBS-T (0.1% Tween 20) 1h at RT. 
Primary antibodies were incubated at +4˚C overnight. The following primary 
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antibodies were used: rabbit anti-Bad (1:1000), rabbit anti-Bax (1:1000), rabbit anti-
Bim (1:1000), rabbit anti-Bok (1:1000), rabbit anti-Puma (1:1000) were procured 
from Cell Signaling Technology (Beverly, MA, USA); rabbit anti-CXCR4 (1:500) 
and goat anti-CD20 (1:250) were from Abcam; mouse anti-PARP (1:500) and anti-
Mcl-1 (1:1000) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The 
appropriate secondary antibodies were from Zymed (S.San Francisco, CA, USA). 
Blots were developed with enhanced chemiluminescence detection method (ECL 
kit, Amersham Pharmacia Biotech, Buckinghamshire, UK). Multiple exposures were 
taken at different times, so that nonsaturated ECL film was used for quantitation. 
Films were digitized by a flatbed transparency scanner and quantified with Java 
domain NIH Image J software (v1.31 freely available at 
http://rsb.info.nih.gov/ij/index.html). 
 
4.10. RNA isolation (III) 
HF4.9 cells (4-6x106) were treated with curcumin for 0, 8, 24 or 36 h. At the end of 
experiment, a sample of cells was assayed for viability using SYTO16/PI staining to 
verify cells´ response to the treatment. Subsequently, cells were harvested, and total 
RNA was isolated using TRI Reagent (Ambion), according to the manufacturer's 
instructions. The quality and integrity of the extracted RNAs were analyzed by gel 
electrophoresis and by spectrometric analysis at 260/280 nm. The experiment was 
performed in quadruplicate maintaining the same conditions. For each time point, 
equal quantities of total RNA were pooled from two independent experiments.  
 
4.11. Large-scale gene expression profiling (III) 
4.11.1. Probe preparation 
Total RNA was processed for hybridization in Finnish DNA Microarray Centre at 
Turku Centre for Biotechnology. Briefly, 300ng total RNA was amplified overnight 
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(14h) with Illumina RNA TotalPrep Amplification kit (Ambion). During IVT 
reaction cRNA was biotinylated. Prior to and after the amplifications the 
RNA/cRNA concentrations where checked with Nanodrop ND-1000 and 
RNA/cRNA quality was controlled by BioRad´s Experion electrophoresis station. A 
hybridization mixture containing 1.5µg of biotinylated cRNA was then hybridized to 
Sentrix Human WG-6 BeadChips (Illumina, Inc., San Diego, CA, USA) at 55ºC 
overnight (19h). 
 
4.11.2. Bead chip microarrays 
In publication III, Sentix Human-WG6 Expression BeadChips (Illumina) were used 
to analyze the curcumin-triggered reprogramming. The Human-WG6 Expression 
BeadChip allows profiling of six individual samples in parallel, >48,000 transcripts 
each. Each sample is probed by a pair of arrays. One stripe in each array pair is 
based on National Centre for Biotechnology Information (NCBI) Reference 
Sequence (RefSeq) genes, with probe content that is well annotated. The second 
stripe includes probes for genes with unique locations in the human genome such as 
ESTs. Probes are specifically designed to avoid querying pseudogenes and SNP 
sites. The arrays are separated from one another by a seal, and thus each can be 
hybridized to a different sample [Steemers and Gunderson; 2005].  
 The array substrate contains wells in a highly ordered, pre-defined pattern. 
Oligonucleotide probes (29-base address concatenated to a 50-base gene-specific 
probe) are immobilized onto beads (approximately 3µm in size) that are 
subsequently quantitatively pooled. Libraries of beads are self-assembled into the 
etched microwell array substrates (Fig. 6).  
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Figure 6. The outline of BeadArray technology. A) The Sentrix BeadChip is created 
using a MEMS-patterned slide substrate. B) Gene-specific probes are immobilized 
on beads. Actual beads have hundreds of thousands of copies of the same sequence 
attached. C) Beads are quantitatively pooled and subsequently self-assembled into 
the patterned substrate. D) Scanning electron micrograph of an assembled array 
containing 3 µm diameter silica beads. Modified from Steemers and Gunderson, 
2005. 
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Each bead in every array contains hundred of thousands of covalently attached 
oligonucleotide probes, and each bead type has an average 30-fold representation, 
providing statistical accuracy of multiple measurements. Finally, each bead on the 
array is identified by virtue of hybridization-based decoding procedure, 
simultaneously validating the performance of each bead type.  
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Several control categories are included into Sentrix BeadArrays: i) controls for the 
biological specimen; ii) controls for sample labeling (optional); iii) controls for 
hybridization (Cy3-labeled Hyb control, low stringency Hyb control, high stringency 
Hyb control), iv) signal generation controls; v) negative controls 
 
Recently, an evaluation of the reproducibility of microarray results using two 
platforms: Affymetrix GeneChip and Illumina BeadChip revealed very high data 
reproducibility [Barnes et al., 2005]. 
 
4.11.3. qRT- PCR 
12µg total RNA from each time point was pooled from 2-4 independent 
experiments, and DNase-treated (DNA-free kit, Ambion) according to 
manufacturer´s instructions, followed by spectrometric analysis. Next, 5µg RNA 
was reverse transcribed using High Capacity cDNA Archieve Kit (Applied 
Biosystems, Warrington, UK), following manufacturer's instructions. cDNA 
dilutions (1:50), and standard series (serial dilutions of pooled cDNA samples) were 
prepared. The amplification of target genes was carried out using 12ng of template 
(RNA equivalents), gene specific primers (QuantiTect Primer Assays, Qiagen), and 
SYBR Green Master Mix PCR (Qiagen), in total volume of 25µl using a RotorGene 
3000 thermocycler (Corbett Research, Sydney, Australia). Dissociation curves were 
analyzed to ensure only a single product was amplified. Data were normalized to b-
actin mRNA expression, and Student´s t test was used to assess the differences in 
relative gene expression.  
4.12. Data analysis 
4.12.1. Microarray data analysis (III) 
Gene profile files from BeadStudio were saved as tab delimited .txt files. Genome 
file corresponding to Sentix Human-WG6 Expression BeadChips was obtained from 
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Illumina. Genome file and gene profile data files were up-loaded to GeneSpring 7.2 
software (Silicon Genetics, Redwood City, CA, USA). The outline of data analysis 
is presented on Fig. 7. Briefly, raw data were normalized to baseline arrays (control), 
and genes with detection precision value >0.95 in at least 2 out of 8 samples were 
filtered (14719 probes passed the requirement). Next, genes with ≥2-fold change at 
least 1 of the 3 comparisons (control versus 8, 24 or 36 hours) were filtered. Using 
the 5% false discovery rate (FDR) 99 targets were found to be modulated by 
curcumin. K-means clustering was applied to the significant genes using standard 
correlation analysis as implemented in the Gene Spring 7.2 program, resulting in 
groupings based on general pattern of expression changes with time following 
curcumin addition. Genes were also grouped based on their molecular function, as 
provided in Gene Spring software. Information on genes was obtained from NCBI. 
 
Figure 7. Workflow of microarray data analysis applied in the present study 
(publication III) 
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5. RESULTS AND DISCUSSION 
 
“All truths are easy to understand once they are discovered; the point is to discover 
them” 
Galileo Galilei 
 
5.1. HA14-1 as an effective inducer of apoptosis (Publication I) 
HA14-1 is a small molecule inhibitor of Bcl-2 protein, found through a computer 
screening strategy and confirmed by a competitive binding assay based on 
fluorescence polarization [Wang et al., 2000] (Fig. 8).  
 
Figure 8 Structure of HA14-1 (A) and model for the complex of HA14-1 with the 
Bcl-2 surface pocket [Wang et al., 2000].  
 
 
 
 
 
 
 
 
The pro-apoptotic activity of HA14-1 has been suggested to correlate positively with 
the level of Bcl-2 in treated cells [Lickliter et al. 2003]. Surprisingly, the action of 
the compound has not been studied in follicular lymphoma cells with physiological 
over-expression of Bcl-2. We demonstrated that HA14-1 is an effective trigger of 
apoptosis in the 3 FL-derived cell lines, as depicted by morphological changes 
(chromatin condensation, nuclear fragmentation, and formation of apoptotic bodies), 
loss of SYTO16 fluorescence, and fractional DNA content ([Skommer et al. 2006]; 
not included in the present thesis). 
A B 
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In publication I we reported that HA14-1 triggers rapid, yet relatively transient, 
mitochondrial membrane depolarisation, in a partially PT-dependent manner. 
Importantly, applying multivariate flow cytometry analysis, we observed that only 
fraction of cells with mitochondrial breach was characterized by concomitant 
caspase activation. Based on the kinetics and pharmacological inhibitor studies, 
coupled with the lack of cell population with active caspases but preserved 
mitochondrial membrane potential in multiparametric flow cytometry assays, we 
concluded that HA14-1- triggered caspase activation occurs solely as a consequence 
of mitochondrial rupture. The outline of the findings has been depicted in Figure 9. 
 
Figure 9 Proposed model for HA14-1 action in follicular lymphoma cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Often, the cell cycle specificity of anti-tumour agents, which is deduced from in 
vitro studies, provides rationale for design of treatment protocols. The analysis of 
cell cycle specificity of HA14-1-evoked apoptosis in vitro revealed that mostly cells 
from the G1 phase undergo apoptosis. Transient exposure to a high dose of the 
compound appeared to induce apoptosis mainly in G1 and S-phase cells, suggesting 
that drugs arresting cells in G1 and/or S phase, or those inducing cell demise from 
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G2/M phase, could be successfully employed with HA14-1 in combinatorial 
regimens.  
In conceptual agreement to our findings, the group headed by Prof. Rosenberg 
published an excellent paper showing the action of newly synthesized Bcl-2 
inhibitor, ABT-737, in cancer cell lines and in vivo models [Oltersdorf et al. 2005]. 
Among others, it was shown that ABT-737 administered as single agent is able to 
induce apoptosis in cell lines with t(14;18) and in cells derived from patients with 
follicular lymphoma, strongly supporting our observations, and firmly confirming 
the potential of Bcl-2 inhibitors in a fight against FL. According to a recent proposal 
by Certo et al. [2006], the BH3-only proteins induce apoptosis in a single-agent 
treatment scenario only in cells poised to die, i.e. cells that rely on the presence of 
anti-apoptotic Bcl-2 proteins. It is possible that in these cells direct activators of Bax 
and Bak, or alternatively Bax and Bak themselves, are engaged to induce cell death 
and are kept in check by one or more of the anti-apoptotic Bcl-2 family members. If 
this is the case, neutralization of anti-apoptotic Bcl-2 proteins causes death (so called 
"death by default"), as observed in FL cells. 
Importantly, certain approaches to sensitize cells to the action of small molecule 
Bcl-2 proteins inhibitors have already been tested, such as pharmacological 
improvement or co-administration with ursodeoxycholic acid (UDCA) - a relatively 
non-toxic bile acid causing a conformational change in Bcl-2 and thus promoting 
HA14-1 binding [Castelli et al. 2004]. Only recently a novel approach to limit 
toxicity and improve water solubility of small molecule Bcl-2 inhibitors has been 
developed [Oman et al. in press]. Certainly antagonists of Bcl-2 family proteins hold 
significant promise for the future of cancer therapy. 
 
5.2. Characterization of curcumin-induced apoptosis (Publication II) 
Inferred from the observation that curcumin can decrease Bcl-2 expression and 
induce apoptosis in several cell lines of hematopoetic origin, we attempted to 
analyze its action in FL cell lines. Although it has been suggested that ectopic over-
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expression of Bcl-2 may attenuate curcumin´s action, FL cell lines appeared to be 
very sensitive to cytotoxic, anti-proliferative and pro-apoptotic action of this 
polyphenol. Caspase-dependency of curcumin-evoked apoptosis has been 
demonstrated by employing z-VAD-fmk titration study. Often applied at relatively 
high concentrations (50-100µM), zVAD-fmk reportedly inhibits not only caspases, 
but also other proteases involved in the execution of cell death, such as calpains and 
cathepsins [Rozman-Pungercar et al. 2003]. However, curcumin-induced loss of cell 
viability was restored already at 30µM dose of zVAD-fmk, underscoring the crucial 
involvement of caspases. Intriguingly, increase in intracellular ROS appeared to act 
as an upstream signal that commenced apoptosis. Lysosomal rupture, observed in all 
cell lines tested, presents a perplexing snippet in the process of curcumin-induced 
cell death. Specifically, it suggests the existence of additional cell death pathways, 
apart from mitochondrial pathway, of cell death. It will be interesting to dissect 
whether mitochondria and lysosomes both contribute to cell fate in this model, or 
whether any of these organelles has an up-stream role in cell death induction. As the 
application of pharmacological inhibitors of cathepsins and calpains exert highly 
lethal effects on FL cell lines, additional studies, including genetic knock-down or 
knock-out experiments, are necessary to elucidate the role of proteases present in 
lysosomal lumen in the progression and phenotypic outcome of curcumin-triggered 
apoptosis. 
  
The major obstacle in the design of effective anticancer curcumin-based therapies is 
a low bioavailability of the polyphenol. Accordingly, we seek to identify agents able 
to sensitize FL cells to curcumin-elicited apoptosis. As co-administration with 
piperine, the active ingredient of black pepper, reportedly enhances curcumin 
bioavailability by 2,000% in human volunteers [Shoba et al. 1998], we first tested its 
ability to enhance curcumin-triggered cell killing in vitro. However, no enhancement 
in any of the growth variables was observed upon co-administration with 
physiologically relevant concentrations of piperine (JS, unpublished observations). 
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Surprisingly though, ascorbic acid appeared to augment curcumin-induced 
cytotoxicity and apoptosis in all FL cell lines tested, an effect associated with and 
dependent on synergistic ROS generation. The pro-oxidant role of ascorbic acid has 
been previously reported both in vitro and in vivo, and on-going controversies on 
ascorbic acid and its pro/anti-oxidant activity exist. Considering the widespread of 
data published up to date, it appears that action of ascorbic acid highly depends on 
its dose, the cellular context, and presence of other compounds, e.g. iron. 
 
Clearly, these experiments proved that curcumin is a trigger of the multilayered 
response in follicular lymphoma cells, and guided the subsequent attempt to provide 
further insights into molecular mechanisms underlying the action of this polyphenol 
using large scale gene expression profiling. 
 
5.3. Global gene expression reprogramming induced by curcumin 
(Publication III) 
 In our search for delineating the molecular mechanisms behind anti-tumour 
activity of curcumin, we went on to determine the large scale gene expression 
reprogramming induced in response to curcumin administration in vitro. Our study 
was the first to address the global gene expression changes following curcumin 
treatment in follicular lymphoma cells, and the first to analyse such a wide range of 
mRNA species upon curcumin treatment in general.  
 In line with previously observed induction of apoptosis, and inhibition of cell 
growth and glucose metabolism, proliferation in FL cell lines treated with curcumin, 
the polyphenol appeared to induce complex genetic reprogramming in HF4.9 cells. 
Genes encoding proteins involved in the regulation of apoptosis, REDOX, cell 
motility, transcription, splicing, ion homeostasis, intracellular signalling, lymphoid 
development, B-cell activation, and others, were identified as curcumin-regulated. In 
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total, 97 mRNA species were recognized as curcumin-responsive, and tables 
summarizing both up- and down-regulated ones can be found from publication III.  
Importantly, prolonged exposition to curcumin was required to sustain many of gene 
expression changes. This is in line with other reports showing, that 24-48h exposure 
to curcumin is necessary for maximal induction of apoptosis [Everett et al. 2007].  
Therefore, and combined with rapid inactivation by hepatic and intestinal 
glucoronidation, the systemic treatment of follicular lymphoma with curcumin in a 
single-agent treatment scenario would require constant intravenous infusion. Thus, 
identification and development of combinatorial treatment regimens with 
compounds improving curcumin´s bioavailability and/or lowering threshold for 
curcumin-induced apoptosis are currently the primary and active research area. 
 
5.3.1. CXCR4 
  Of great importance, among panoply of curcumin-responsive genes the 
CXCR4 gene was markedly down-regulated, a finding confirmed by both qRT-PCR 
and immunoblotting. The effect was observed in all FL cell lines tested. As the 
major obstacle in the successful administration of curcumin is its low bioavailability 
in vivo, we also asked whether low but attainable in vivo doses of curcumin are able 
to down-regulate CXCR4 over longer treatment times. FL cell lines were cultured 
with 2µM curcumin for 5 days (single curcumin administration in day 0), followed 
by protein isolation and immunoblotting. Surprisingly, even at such a low 
concentration curcumin largely reduced the expression of CXCR4 protein in all cell 
lines tested. Since interfering with CXCR4 function by means of pharmacological 
inhibitor AMD3100 retarded long-term cell growth and induced cell death in a cell 
line dependent fashion, it is plausible to reason that down-regulation of CXCR4 may 
have a correlate to the growth-suppresive effects of curcumin in some cellular 
contexts.  
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The CXCR4 receptor is broadly expressed not only on a wide variety of leukocytes, 
but also on cells outside immune system, and its cell surface expression was 
detected in all 3 FL cell lines utilized in the present study (Fig. 10). 
 
Figure 10 Cell surface CXCR4 expression in FL cell lines. Thin line histograms 
indicate cells stained with isotype control Ab, whereas thick line histograms indicate 
cells stained with anti-CXCR4 mAb. 
 
 
 
 
 
 
 
In contrast to other chemokine receptors, CXCR4 is activated by a single chemokine 
ligand, stromal cell-derived factor (SDF-1, now designated as CXCL12). This 
monogamous relation was confirmed by studies on Cxcl12 and Cxcr4 gene-deleted 
mice. The CXCR4-CXCL12 axis is functional in evolutionarily distant organisms 
such as zebra fish and mice, and plays an important role in hematopoiesis, 
development, organization of the immune system, and tissue repair and regeneration. 
CXCR4 and its cognate ligand have also profound influence on cancer progression. 
Commonly observed low oxygen levels within the tumour (hypoxia) trigger 
expression of hypoxia-inducible factor 1 (HIF-1), which in turn induces expression 
of CXCR4. This provides a possible mechanism that accounts for increased CXCR4 
expression during tumour cell evolution. CXCL12 is secreted by marrow-derived 
stromal cells, which attracts cancer cells and supports the survival or growth of a 
variety of malignant cell types, including leukaemia B cells. CXCL12 can also 
promote tumour angiogenesis by attracting endothelial cells to the tumour 
microenvironment. CXCR4 is essential for metastatic spread to CXCL12-expressing 
HF1A3 HF4.9 HF28RA
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organs, such as the marrow, and recirculation of cancer cells between the blood and 
the marrow or lymphoid tissue, where they receive protective survival signals 
[Burger and Kipps, 2006]. Indeed, ample evidence suggest that CXCR4 is crucial in 
the trafficking of hematopoietic malignancies, such as B-cell chronic lymphocytic 
leukaemia (CLL), multiple myeloma, non-Hodgkin lymphomas (including follicular 
lymphomas), and acute leukemias (ALL, precursor B-cell acute lyphoblastic 
leukaemia and AML, acute myelogenous leukaemia). It is also involved in anti-
cancer drug resistance, as many cells become resistant to spontaneous or drug-
induced apoptosis upon adhesion to marrow stromal fibronectin. As CXCR4 appears 
to be a linchpin in the context of crosstalk between tumour cells and their respective 
microenvironment, CXCR4-targeted therapeutic approaches may soon prove to be 
clinically relevant. Therefore, the concept that well tolerated natural compound 
curcumin impedes CXCR4 expression is seminal for the future clinical assessment 
of curcumin as the innovative therapeutic option for follicular lymphoma patients. 
 Although the present study clearly indicates that curcumin down-regulates the 
CXCR4 gene expression in FL cell lines, a number of questions remain to be 
answered: 1) what is the mechanism underlying curcumin-mediated down-regulation 
of CXCR4 and how does it contribute to the process of apoptosis?; 2) is it an effect 
ascribed only to FL cells, or could it be observed in a wider range of tumour cells? ; 
3) can tumour cells develop resistance to curcumin-induced CXCR4 down-
regulation? ; 4) does (and if yes, how) this in vitro effect translate to the situation in 
vivo? Specifically, does curcumin treatment decrease CXCR4 expression in cancer 
cells in vivo, and can curcumin inhibit homing of circulating malignant cells to the 
sites rich in SDF-1 in animal models?; and 5) can curcumin mobilize normal 
hematopoietic progenitor cells in a manner analogical to CXCR4 antagonists? As the 
interest in function of CXCR4-SDF1 axis in tumour dissemination is mushrooming, 
we are unlikely to await the answers for long. 
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5.3.2. CD20 
Targeting epitopes virtually restricted to lymphoproliferative malignancies 
and normal lymphoid tissues represents a rapidly evolving field of established and 
innovative treatment options. The antigen CD20 is expressed on nearly all B-cell 
lymphomas, does not internalize or shed from the surface in response to antibody 
binding and is absent in plasma cells and hematopoietic stem cells. Thus, it 
represents the prototypic target antigen for antibody-based therapy of malignant B-
cell lymphomas. The exact in vivo function of CD20 remains mostly unknown, as no 
physiologic ligand has been described and in CD20-deficient knock-out mice several 
immunological features such as B-cell development, tissue localization, signal 
transduction, or proliferation remain unaffected [Uchida et al. 2004]. However, new 
evidence has been provided recently in support of the role of CD20 in 
transmembrane Ca2+ calcium movement in mouse primary B cells [Uchida et al. 
2004]. 
In microarray screening for curcumin-induced gene expression 
reprogramming the CD20 gene appeared to be significantly down-regulated at any 
treatment time, a finding confirmed by qRT-PCR and immunoblotting (compare Fig. 
11). 
 
 
Figure 11 Expression of CD20 in control (-) and curcumin–treated HF1A3, HF4.9 
and HF28RA cells. The intensity of the bands was normalized against that of actin 
and control.  
 
 
 
 
 
 
- CUR - CUR - CUR
HF1A3 HF4.9 HF28RA
CD20 
    1         0.64     1        0.80   1        0.52 
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Although the information on the role of CD20 is still limited, the observation that 
curcumin induces a marked decrease in CD20 expression hints for possible clinical 
implications, brings new questions, and also suggests further experimental work to 
be done: 1) Potentially, down-regulation of CD20 may have adverse effects on the 
efficacy of anti-CD20 therapy in B-cell malignancies; hence the in vitro and in vivo 
effects of combinatorial treatment with curcumin and anti-CD20 mAbs should be 
assessed; 2) anti-CD20 mAbs exert different effects on B cells depending on their 
stage of differentiation. It will be interesting to test whether effects of curcumin on 
CD20 expression are also differentiation-dependent; 3) As in the case of CXCR4, 
the specificity of curcumin-mediated down-regulation of CD20 in FL cell lines as 
compared to normal B cells and other tumour cell lines/primary cells, as well as 
effects of curcumin on CD20 expression in vivo should be examined; 4) Does CD20 
down-regulation contribute to curcumin-induced apoptosis? Again, I hope for at 
least some of these queries to be deciphered soon. 
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5.4. CXCR4 down-regulation is not a common apoptosis-associated event 
(Publication IV) 
 The final and important question here was whether CXCR4 down-regulation 
is commonplace in dying cells. The scarcity of data on CXCR4 expression during 
tumour cell demise, coupled with our original observation that curcumin down-
regulates CXCR4 expression at both mRNA and protein levels, prompted us to 
study the generality of the phenomenon on treatment with pro-apoptotic agents 
targeting different organelles/pathways (Fig. 12), including anti-CD95 mAb (death 
receptor pathway), HA14-1 (mitochondrial pathway), doxorubicin (DNA damage), 
vincristine (microtubule depolymerization), and inducer of ER-stress brefeldin A 
(BFA) . 
 
Figure 12 Schematic representation of apoptotic pathways targeted to access the 
CXCR4 expression during apoptotic cell death.  
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Additionally, to investigate CXCR4 expression during non-apoptotic cell death, 
HF1A3 cells were stimulated with 3% H2O2 for 15min, when HF1A3 cells die via 
oncosis. Interestingly, we did not detect CXCR4 down-regulation in any of the 
abovementioned treatment scenarios. These data indicate that i) CXCR4 protein 
down-regulation is not commonly observed during tumour cell death; and ii) 
curcumin is a specific inducer of CXCR4 down-regulation in our model. 
Considering the role of CXCR4 in vivo, the above results suggest also the 
superiority of curcumin over traditional anticancer drugs (Dox, Vin), and 
compounds in clinical development as anti-cancer agents (HA14-1, BFA), in 
management of local and distant tumour metastasis.  
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6. CONCLUSIONS, CLINICAL IMPLICATIONS AND FUTURE 
DIRECTIONS 
 
The seminal discovery that the BCL2 gene inhibits cell death rather than promotes 
cell proliferation [Vaux et al. 1988, McDonnell et al. 1989] gave foundation for now 
widely embraced premise that impaired apoptosis is a crucial step in tumorigenesis. 
Indeed, disturbances in regulation of selective cell death underlie many diseases, 
including cancer, autoimmunity and degenerative disorders, and the antitumour 
effects of anticancer drugs are linked to their ability to induce apoptosis within 
tumours. Nevertheless, other forms of cell demise, such as autophagic cell death or 
necrosis, might also be induced by chemotherapy. Clearly, studies on molecular 
mechanisms behind any type of programmed cell death should benefit our 
understanding of the effects of anticancer agents and represent a research market 
that will continue to grow. 
  
Intrinsic and/or acquired resistance to autophagic cell death and apoptosis may result 
in resistance to anticancer drugs. The Achilles´ heel of most of the tumour cells is 
that they remain sensitive to some apoptotic triggers, and thus agents stimulating 
certain proapoptotic proteins and/or signalling pathways represent promising 
strategies to combat cancer. Moreover, targeting alternative cell death routes in cells 
resistant to apoptosis or cells in which apoptosis is inhibited, as well as combining 
both apoptosis-inducing and survival suppressing strategies, may appear clinically 
advantageous. 
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The concluding remarks based on the results summarized above and reported in 
Publications I-IV are as follows: 
  
1. HA14-1, a BH3 mimetic, induces partially PT-dependent apoptosis in 
follicular lymphoma cells in a single agent regimen (Publication I) 
Small molecule inhibitors of Bcl-2 (e.g. HA14-1) represent an alternative strategy to 
induce apoptosis in follicular lymphoma cells even in a single agent treatment 
scenario, and thus FL cells can be considered as primed for death. Mechanistically, 
HA14-1-evoked caspase activation occurs solely as a consequence of mitochondrial 
rupture, and ensuing cell death is partially PT-dependent. Bcl-2 antagonists first 
emerged as compounds that should potentially sensitize cells to the action of other 
stress stimuli such as anticancer drugs or growth factor withdrawal. However, FL 
cells exposed to BH3 mimetic HA14-1 readily undergo cell death without any 
additional stress stimuli, suggesting that they are primed for death, and underlying 
that they indeed may be susceptible to targeting by drugs developed as mimetics of 
sensitizer BH3 domains. 
 
2. Cellular basis of curcumin-induced cell death (Publication II) 
Curcumin induces cessation of FL cell growth at attainable in vivo 1µM 
concentration, and is an efficient inducer of apoptosis at higher concentrations. The 
pro-apoptotic effects of curcumin are enhanced by physiologically relevant doses of 
ascorbic acid, warranting clinical studies on curcumin-based therapies in follicular 
lymphoma patients. Follicular lymphoma is an indolent disease, with a watchful 
waiting strategy considered as an appropriate treatment option for patients 
presenting early stages of FL. Hence, the safe and patient-friendly dietary approach, 
such as administration of curcumin, may represent an alternative strategy with 
chemopreventive and/or tumour suppressing potential.  
Mechanistically, caspases are essential for curcumin-induced apoptosis in FL cells, 
whereas the pertinence of lysosomal proteases in the propagation and phenotypic 
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outcome of cell death in this model remains to be dissected. Due to inherent cell 
death associated with exposition to calpain and/or cathepsin inhibitors, this will 
require genetic manipulation in a tightly regulated manner. It is indeed of great 
importance, especially because cell death pathways other than classical apoptosis 
(such as autophagic cell death) are increasingly recognized to contribute to overall 
level of drug-induced cell killing. 
 
 
3. Curcumin induces CXCR4 downregulation, which is not a cell-death 
associated event (Publication III and IV) 
Curcumin induces complex gene expression changes in HF4.9 cells, including 
down-regulation of CXCR4 both at mRNA and protein levels. Based on the 
literature data available up to date, CXCR4 down-regulation should be of supreme 
importance for the therapeutic effects of curcumin in vivo. FL is recognized as a 
disease of functional B cells in which the clinical behaviour is determined not only 
by deregulated apoptotic-pathways within the malignant cells, but also by functional 
cross-talk with the immunologic regulatory network. Hence, curcumin may interfere 
with survival of B lymphoma cells in survival niche, where they receive enough 
microenvironmental signals to resist chemotherapy-triggered cell death. Moreover, 
as CXCR4-CXCL12 axis is thought to be involved in lymphoma cell trafficking and 
dissemination, and CXCR4-deficient hybridoma cells reportedly fail to disseminate 
to CXCL12-expressing target organs, curcumin may also inhibit metastasis of FL 
cells. Gene expression reprogramming triggered by curcumin appears to require 
sustained exposition to the compound, supporting the premise of a prolonged 
curcumin administration being therapeutically beneficial over short-term treatment. 
Finally, CXCR4 down-regulation, observed during curcumin-induced apoptosis, is 
not generic to cell death underlying the advantage of curcumin over traditional 
chemotherapeutics.   
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